<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="http://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="79f328f1-ce1a-435e-9540-6e14374989d6"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>These highlights do not include all the information needed to use CELECOXIB CAPSULESÂ safely and effectively. See full prescribing information for CELECOXIB CAPSULES.<br/>
      <br/>CELECOXIB capsules, for oral use<br/>Initial U.S. Approval: 1998<br/>
   </title>
   <effectiveTime value="20170620"/>
   <setId root="03c40e1c-c274-48d9-9c70-5f2a670e49cc"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="080072003" root="1.3.6.1.4.1.519.1"/>
            <name>Cambridge Therapeutics Technologies, LLC</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="3c2cf7bc-68ce-45f4-a196-234c47a1ebaf"/>
               <code code="48780-1" displayName="SPL LISTING DATA ELEMENTS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20170620"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70882-129" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Celecoxib</name>
                        <formCode code="C25158" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Celecoxib</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="65862-909" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="200"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="JCX84Q7J1L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELECOXIB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="JCX84Q7J1L" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CELECOXIB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2S7830E561" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="RFW2ET671P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYPROPYL CELLULOSE (TYPE H)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="U725QWY32X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE K30</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7CV7WJK4UI" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STEARYL FUMARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="14"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="70882-129-14" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" displayName="BLISTER PACK" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20160201"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA206827" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20160201"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="WHITE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">Y;200</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="18" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_c02b5aa9-3bd2-45bd-8cda-a34b695d4ed7">
               <id root="c02b5aa9-3bd2-45bd-8cda-a34b695d4ed7"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <title>RECENT MAJOR CHANGES</title>
               <effectiveTime value="20160517"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Boxed WarningÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 5/2016<br/>Warnings and Precautions, <br/>Cardiovascular Thrombotic EventsÂ <linkHtml href="#LINK_d3863c12-5bb3-4999-8cbe-53ff3302917d">(5.1)</linkHtml>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 5/2016<br/>Warnings and Precautions, Heart Failure and EdemaÂ <linkHtml href="#LINK_87f8faba-2740-4011-a06c-b2662ad92372">(5.5)</linkHtml>Â Â Â Â Â Â Â Â Â  5/2016</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_b39d30bb-5fbd-4132-8978-4d148679801b">
               <id root="b39d30bb-5fbd-4132-8978-4d148679801b"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="underline"> Cardiovascular</content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="underline"> Thrombotic</content>
                     </content>
                     <content styleCode="xmChange">
                        <content styleCode="bold">
                           <content styleCode="underline"> Events</content>
                        </content>
                     </content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>
                        <content styleCode="bold">Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction, and stroke, which can be fatal. This risk may occur earlyÂ <content styleCode="xmChange">in</content> the treatment and may increase with duration of use. [<content styleCode="italics">seeÂ <linkHtml href="#LINK_d3863c12-5bb3-4999-8cbe-53ff3302917d">Warnings andÂ Precautions (5.1)</linkHtml>
                           </content>]</content>
                     </item>
                     <item>
                        <content styleCode="bold">Celecoxib is contraindicatedÂ <content styleCode="xmChange">in</content> the setting of coronary artery bypass graft (CABG) surgery. [<content styleCode="italics">seeÂ <linkHtml href="#LINK_4e64c33b-fc94-493c-9ebc-d5f9c2eeeaa0">Contraindications (4)</linkHtml> and <linkHtml href="#LINK_d3863c12-5bb3-4999-8cbe-53ff3302917d">Warnings and Precautions (5.1)</linkHtml>
                           </content>]</content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="underline"> Gastrointestinal</content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="underline"> Bleeding,</content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="underline"> Ulceration,</content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="underline">Â </content>
                     </content>
                     <content styleCode="xmChange">
                        <content styleCode="bold">
                           <content styleCode="underline"> and</content>
                        </content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="underline"> Perforation</content>
                     </content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>
                        <content styleCode="bold">NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforationÂ <content styleCode="xmChange">of</content> the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious (GI) events. [<content styleCode="italics">see <linkHtml href="#LINK_5069f2c7-1a91-4542-a9be-3aa4f8dbb0bc">Warnings and Precautions (5.2)</linkHtml>
                           </content>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20160517"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold"> WARNING: RISK  OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS<br/>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics"> See full prescribing information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Â </content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>
                              <content styleCode="bold"> Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic  events, including myocardial infarction and stroke, which  can be fatal. This risk may  occur early in  the treatment and may  increase with  duration of  use.Â <linkHtml href="#LINK_d3863c12-5bb3-4999-8cbe-53ff3302917d">(5.1)</linkHtml>
                              </content>
                           </item>
                           <item>
                              <content styleCode="bold">Celecoxib  is contraindicated in  the setting of coronary artery bypass graft  (CABG) surgery.Â <linkHtml href="#LINK_4e64c33b-fc94-493c-9ebc-d5f9c2eeeaa0">(4</linkHtml>, <linkHtml href="#LINK_d3863c12-5bb3-4999-8cbe-53ff3302917d">5.1)</linkHtml>
                              </content>
                           </item>
                           <item>
                              <content styleCode="bold"> NSAIDs cause an  increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of  the stomach or intestines, which  can be fatal. These events can  occur at any time during use  and without warning symptoms. Elderly patients and  patients with a  prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events. <linkHtml href="#LINK_5069f2c7-1a91-4542-a9be-3aa4f8dbb0bc">(5.2)</linkHtml>
                              </content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_06fa04dc-2694-433d-98ab-a35bad21e13b">
               <id root="06fa04dc-2694-433d-98ab-a35bad21e13b"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1. INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Celecoxib capsules are indicated</paragraph>
               </text>
               <effectiveTime value="20160517"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Celecoxib is a nonsteroidal anti-inflammatory drug indicated for:</paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>Osteoarthritis (OA) <linkHtml href="#LINK_9d27ef8d-68d8-43f0-97f7-3119e59992ed">(1.1)</linkHtml>
                           </item>
                           <item>Rheumatoid Arthritis (RA) <linkHtml href="#LINK_3ed82db1-c254-42a0-94be-bc64f700adee">(1.2)</linkHtml>
                           </item>
                           <item>Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older <linkHtml href="#LINK_9360587a-eb2c-4415-8c4c-731d853a96b9">(1.3)</linkHtml>
                           </item>
                           <item> Ankylosing Spondylitis (AS)Â <linkHtml href="#LINK_c3124122-a0a6-4854-b8e2-2289c573b66b">(1.4)</linkHtml>
                           </item>
                           <item>Acute Pain (AP) <linkHtml href="#LINK_c409401c-94c4-4403-8b01-5f9b4524836f">(1.5)</linkHtml>
                           </item>
                           <item>Primary Dysmenorrhea (PD) <linkHtml href="#LINK_952da148-82d4-4866-82e7-5f8d51d0ebb6">(1.6)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_9d27ef8d-68d8-43f0-97f7-3119e59992ed">
                     <id root="9d27ef8d-68d8-43f0-97f7-3119e59992ed"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Osteoarthritis (OA)</title>
                     <text>
                        <paragraph>For the management of the signs and  symptoms of OA [<content styleCode="italics">see <linkHtml href="#LINK_8031dd46-6144-4922-905d-d347808f267d">Clinical Studies (14.1)</linkHtml>
                           </content>]</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_3ed82db1-c254-42a0-94be-bc64f700adee">
                     <id root="3ed82db1-c254-42a0-94be-bc64f700adee"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Rheumatoid Arthritis (RA)</title>
                     <text>
                        <paragraph>For the management of the signs and  symptoms of RA [<content styleCode="italics">see <linkHtml href="#LINK_7110df1c-07ac-4450-b492-3db14795a38c">Clinical Studies (14.2)</linkHtml>
                           </content>]</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_9360587a-eb2c-4415-8c4c-731d853a96b9">
                     <id root="9360587a-eb2c-4415-8c4c-731d853a96b9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.3 Juvenile Rheumatoid Arthritis (JRA)</title>
                     <text>
                        <paragraph>For the management of the signs and  symptoms of JRA in patients 2  years and older [<content styleCode="italics">see <linkHtml href="#LINK_5abaaafe-b0a9-4160-832f-e41939fb2282">Clinical  Studies (14.3)</linkHtml>
                           </content>]</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c3124122-a0a6-4854-b8e2-2289c573b66b">
                     <id root="c3124122-a0a6-4854-b8e2-2289c573b66b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.4 Ankylosing Spondylitis (AS)</title>
                     <text>
                        <paragraph>For the management of the signs and  symptoms of AS [<content styleCode="italics">see <linkHtml href="#LINK_330456de-1c3a-47dd-bdce-ff6fd7ba1d42">Clinical Studies (14.4)</linkHtml>
                           </content>]</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c409401c-94c4-4403-8b01-5f9b4524836f">
                     <id root="c409401c-94c4-4403-8b01-5f9b4524836f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.5 Acute Pain</title>
                     <text>
                        <paragraph>For the management of acute pain in adults [<content styleCode="italics">see <linkHtml href="#LINK_8c4c2711-ec6e-4d00-b8e7-30d61e78fe7d">Clinical  Studies (14.5)</linkHtml>
                           </content>]</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_952da148-82d4-4866-82e7-5f8d51d0ebb6">
                     <id root="952da148-82d4-4866-82e7-5f8d51d0ebb6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.6 Primary Dysmenorrhea</title>
                     <text>
                        <paragraph>For the  management  of  primary  dysmenorrhea [<content styleCode="italics">see <linkHtml href="#LINK_8c4c2711-ec6e-4d00-b8e7-30d61e78fe7d">Clinical Studies (14.5)</linkHtml>
                           </content>]</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_3de1f64d-82a0-4d0e-a25f-a6cf26f27190">
               <id root="3de1f64d-82a0-4d0e-a25f-a6cf26f27190"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2. DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20160517"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>Use the  lowest effective dosage for shortest duration consistent  with individual patient treatment goals <linkHtml href="#LINK_be69037f-bb0a-4fa6-8e5c-a52ec70b785a">(2.1)</linkHtml>
                           </item>
                           <item>OA: 200 mg once daily or 100 mg  twice daily  <linkHtml href="#LINK_2a751c4d-4656-4376-9ff0-e0d8afc911af">(2.2</linkHtml>,Â <linkHtml href="#LINK_8031dd46-6144-4922-905d-d347808f267d">14.1)</linkHtml>
                           </item>
                           <item>RA: 100 to 200 mg twice daily <linkHtml href="#LINK_dd16dcf4-01c3-460b-a599-4e790b160701">(2.3</linkHtml>, <linkHtml href="#LINK_7110df1c-07ac-4450-b492-3db14795a38c">14.2)</linkHtml>
                           </item>
                           <item>JRA: 50 mg twice daily in patients 10 to 25 kg. 100 mg twice daily in patients more than 25 kg <linkHtml href="#LINK_c8516fe7-a59f-41e0-a8fa-0858a50a363e">(2.4</linkHtml>, <linkHtml href="#LINK_5abaaafe-b0a9-4160-832f-e41939fb2282">14.3)</linkHtml>
                           </item>
                           <item>AS: 200 mg once daily single dose or 100 mg twice daily. If no effect is observed after 6 weeks, a trial of 400 mg (single or divided doses) may be of benefit <linkHtml href="#LINK_8bd968ee-750d-4e27-8e59-73ec11376506">(2.5</linkHtml>, <linkHtml href="#LINK_330456de-1c3a-47dd-bdce-ff6fd7ba1d42">14.4)</linkHtml>
                           </item>
                           <item>AP and PD: 400 mg initially, followed by 200 mg dose if needed on first day. On subsequent days, 200 mg twice daily as needed <linkHtml href="#LINK_70f2416b-8784-4030-9e86-aae37fcc1771">(2.6</linkHtml>, <linkHtml href="#LINK_8c4c2711-ec6e-4d00-b8e7-30d61e78fe7d">14.5)</linkHtml>
                           </item>
                        </list>
                        <br/>
                        <paragraph>Hepatic Impairment: Reduce daily dose by 50% in patients with moderate hepatic impairment (Child-Pugh Class B). <linkHtml href="#LINK_34b62d78-e046-45be-a205-884e22cd4152">(2.7</linkHtml>, <linkHtml href="#LINK_b8f55895-9834-4cd9-9451-c6e622fef01a">8.6</linkHtml>, <linkHtml href="#LINK_1282d1e7-d3fe-4731-98c7-457eed99b078">12.3)</linkHtml>
                           <br/>
                           <br/>Poor Metabolizers of CYP2C9 Substrates: Consider a dose reduction by 50% (or alternative management for JRA) in patients who are known or suspected to be CYP2C9 poor metabolizers <linkHtml href="#LINK_34b62d78-e046-45be-a205-884e22cd4152">(2.7</linkHtml>, <linkHtml href="#LINK_b780e991-b07c-4c0e-bcfa-c2804559693a">8.8</linkHtml>, <linkHtml href="#LINK_1282d1e7-d3fe-4731-98c7-457eed99b078">12.3)</linkHtml>.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_be69037f-bb0a-4fa6-8e5c-a52ec70b785a">
                     <id root="be69037f-bb0a-4fa6-8e5c-a52ec70b785a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 General Dosing Instructions</title>
                     <text>
                        <paragraph>Carefully consider the potential benefits and risks  of celecoxib capsules and other treatment options before deciding to use celecoxib capsules. Use the  lowest effective dosage for the shortest duration consistent  with individual patient treatment goals [<content styleCode="italics">see <linkHtml href="#LINK_8fb56d51-365d-4978-8b0b-ad0c177262a4">Warnings and Precautions (5)</linkHtml>
                           </content>].<br/>
                           <br/>These doses can be given without regard to timing of meals.</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_2a751c4d-4656-4376-9ff0-e0d8afc911af">
                     <id root="2a751c4d-4656-4376-9ff0-e0d8afc911af"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Osteoarthritis</title>
                     <text>
                        <paragraph>For OA, the dosage is 200 mg per day administered as a single dose or as 100 mg  twice daily.</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_dd16dcf4-01c3-460b-a599-4e790b160701">
                     <id root="dd16dcf4-01c3-460b-a599-4e790b160701"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Rheumatoid Arthritis</title>
                     <text>
                        <paragraph>For RA, the dosage is 100 to 200 mg  twice daily.</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c8516fe7-a59f-41e0-a8fa-0858a50a363e">
                     <id root="c8516fe7-a59f-41e0-a8fa-0858a50a363e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Juvenile Rheumatoid Arthritis</title>
                     <text>
                        <paragraph>For JRA, the dosage for pediatric patients (age 2 years and older) is based on  weight. For patients <content styleCode="underline">&gt;</content>10 kg to <content styleCode="underline">&lt;</content>25 kg the recommended dose is 50 mg  twice daily. For patients &gt;25 kg the recommended dose is 100 mg  twice daily.<br/>
                           <br/>For patients  who have difficulty  swallowing capsules, the contents of a celecoxib capsules can be added to applesauce. The entire capsule contents are  carefully emptied onto a level teaspoon of cool or room  temperature applesauce and ingested immediately  with water. The sprinkled capsule contents on applesauce are stable for up to 6 hours under refrigerated conditions (2 to 8Â°  C/ 35 to 45Â° F).</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_8bd968ee-750d-4e27-8e59-73ec11376506">
                     <id root="8bd968ee-750d-4e27-8e59-73ec11376506"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Ankylosing Spondylitis</title>
                     <text>
                        <paragraph>For AS, the dosage of celecoxib capsules are 200 mg daily in single (once per  day) or divided (twice per day) doses. If no effect is observed after 6  weeks, a trial of 400 mg daily may be  worthwhile. If no effect is observed after 6  weeks on 400 mg  daily, a response is not likely and consideration should be given to alternate treatment options.</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_70f2416b-8784-4030-9e86-aae37fcc1771">
                     <id root="70f2416b-8784-4030-9e86-aae37fcc1771"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Management of Acute Pain and Treatment of Primary Dysmenorrhea</title>
                     <text>
                        <paragraph>For management of Acute Pain and Treatment of Primary  Dysmenorrhea, the dosage is 400 mg initially,  followed by an additional 200 mg dose if needed on the first  day. On subsequent  days, the recommended dose is 200 mg  twice daily as needed.</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_34b62d78-e046-45be-a205-884e22cd4152">
                     <id root="34b62d78-e046-45be-a205-884e22cd4152"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.7 Special Populations</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics"> Hepatic</content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics"> Impairment<br/>
                              </content>
                           </content>
                           <br/>In patients  with moderate hepatic impairment (Child-Pugh Class B), reduce the dose by 50%. The use of celecoxib capsules in patients  with severe hepatic impairment is not recommended [<content styleCode="italics">see <linkHtml href="#LINK_87f8faba-2740-4011-a06c-b2662ad92372">Warnings and Precautions (5.5)</linkHtml>,Â <linkHtml href="#LINK_b8f55895-9834-4cd9-9451-c6e622fef01a">Use in Specific Populations (8.6)</linkHtml> and  <linkHtml href="#LINK_1282d1e7-d3fe-4731-98c7-457eed99b078">Clinical Pharmacology (12.3)</linkHtml>].<br/>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Poor M</content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics">etabolizers o</content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics">f C</content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics">YP2C9 S</content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics">ubstrates<br/>
                              </content>
                           </content>
                           <br/>In adult patients who are known or suspected to be poor CYP2C9 metabolizers based on genotype or previous history/experience with other CYP2C9 substrates (such as warfarin, phenytoin), initiate treatment with half of the lowest recommended dose.<br/>
                           <br/>In patients with JRA who are known or suspected to be poor CYP2C9 metabolizers, consider using alternative treatments. [<content styleCode="italics">see <linkHtml href="#LINK_b780e991-b07c-4c0e-bcfa-c2804559693a">Use in Specific populations (8.8)</linkHtml>, and <linkHtml href="#LINK_5f779a72-3d7d-4f1b-80c5-323ec77a403f">Clinical Pharmacology (12.5)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_4989b3cb-a98a-4803-8add-c68df16de409">
               <id root="35dd14b1-8b9d-448f-890f-69646d1cb043"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3. DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Celecoxib Capsules:<br/>
                     <br/>200 mg white cap/white body, size â2â hard gelatin capsule filled with white to off-white granular powder, imprinted with âYâ on the cap and â200â on the body with gold ink.</paragraph>
               </text>
               <effectiveTime value="20170620"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Celecoxib Capsules:Â 200 mg (<linkHtml href="#LINK_4989b3cb-a98a-4803-8add-c68df16de409">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_4e64c33b-fc94-493c-9ebc-d5f9c2eeeaa0">
               <id root="4e64c33b-fc94-493c-9ebc-d5f9c2eeeaa0"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4. CONTRAINDICATIONS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Celecoxib capsules  are contraindicated in the following patients:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item> Known hypersensitivity  (e.g., anaphylactic reactions and serious skin reactions) to celecoxib, any components of the drug product [see <content styleCode="italics">
                           <linkHtml href="#LINK_06dd8f73-061b-470b-a423-4a7f979e165b">Warnings and Precautions (5.7</linkHtml>, <linkHtml href="#LINK_5c76fc34-dcf3-40cc-b188-315fbbb7ff33">5.9)</linkHtml>
                        </content>].</item>
                     <item>History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs, have been reported in such patients [<content styleCode="italics">see <linkHtml href="#LINK_06dd8f73-061b-470b-a423-4a7f979e165b">Warnings and Precautions (5.7</linkHtml>, <linkHtml href="#LINK_3c3b0eff-1277-499f-bc25-a8f91329efe7">5.8)</linkHtml>
                        </content>].</item>
                     <item>In the setting of coronary artery bypass graft (CABG) surgery [<content styleCode="italics">see <linkHtml href="#LINK_d3863c12-5bb3-4999-8cbe-53ff3302917d">Warnings and Precautions (5.1)</linkHtml>
                        </content>].</item>
                     <item>In patients  who have demonstrated  allergic-type reactions to sulfonamides.</item>
                  </list>
               </text>
               <effectiveTime value="20160517"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item> Known hypersensitivity to celecoxib, or any components of the drug product or sulfonamides <linkHtml href="#LINK_4e64c33b-fc94-493c-9ebc-d5f9c2eeeaa0">(4)</linkHtml>
                           </item>
                           <item>History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs <linkHtml href="#LINK_4e64c33b-fc94-493c-9ebc-d5f9c2eeeaa0">(4)</linkHtml>
                           </item>
                           <item>In the setting  of CABG surgery <linkHtml href="#LINK_4e64c33b-fc94-493c-9ebc-d5f9c2eeeaa0">(4)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_8fb56d51-365d-4978-8b0b-ad0c177262a4">
               <id root="8fb56d51-365d-4978-8b0b-ad0c177262a4"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5. WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20160517"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>
                              <content styleCode="underline"> Hepatotoxicity:</content> Inform patients of  warning signs and  symptoms of  hepatotoxicity. Discontinue if abnormal liver tests persist or worsen or if clinical signs and  symptoms of liver disease develop <linkHtml href="#LINK_123c45b9-a78a-40ef-ae49-d72c8d0bd6ba">(5.3)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="underline">Hypertension</content>: Patients taking  some antihypertensive medications may have impaired response to these therapies  when taking NSAIDs. Monitor blood pressure <linkHtml href="#LINK_7a44f63e-a433-4488-8e48-4e737b9afdf8">(5.4</linkHtml>, <linkHtml href="#LINK_93869e4e-072e-4529-aef5-761fb3a6d1b1">7)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="underline">Heart Failure and Edema</content>: Avoid use of celecoxib in patients  with severe heart failure unless benefits are expected to  outweigh risk of  worsening heart failure <linkHtml href="#LINK_87f8faba-2740-4011-a06c-b2662ad92372">(5.5)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="underline">Renal  Toxicity:</content> Monitor renal function in patients  with renal or hepatic impairment, heart failure, dehydration, or hypovolemia. Avoid use of celecoxib in patients  with advanced renal disease unless benefits are expected to outweigh risk of  worsening renal function <linkHtml href="#LINK_2ce69f4f-9899-4506-91c2-9d2771f1355f">(5.6)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="underline"> Anaphylactic Reactions</content>: Seek emergency help if an  anaphylactic reaction occurs <linkHtml href="#LINK_06dd8f73-061b-470b-a423-4a7f979e165b">(5.7)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="underline">Exacerbation of Asthma Related to Aspirin  Sensitivity:</content> Celecoxib is contraindicated in patients  with aspirin-sensitive  asthma. Monitor patients  with preexisting asthma  (without aspirin  sensitivity)Â <linkHtml href="#LINK_3c3b0eff-1277-499f-bc25-a8f91329efe7">(5.8)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="underline">Serious Skin Reactions</content>: Discontinue celecoxib at first appearance of skin rash or other signs of hypersensitivity <linkHtml href="#LINK_5c76fc34-dcf3-40cc-b188-315fbbb7ff33">(5.9)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="underline">Premature Closure of Fetal Ductus Arteriosus</content>: Avoid use in pregnant  women starting at 30  weeks of gestation <linkHtml href="#LINK_4785b1f6-62b6-4f3b-86f3-1c6d5e6adb2d">(5.10</linkHtml>, <linkHtml href="#LINK_f3aec266-21a6-4ac8-936c-cb2499eb89de">8.1)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="underline">Hematologic  Toxicity:</content> Monitor hemoglobin or hematocrit in patients  with any signs or  symptoms of anemia <linkHtml href="#LINK_c567e811-3129-4615-9802-6c822560bbcc">(5.11</linkHtml>, <linkHtml href="#LINK_93869e4e-072e-4529-aef5-761fb3a6d1b1">7)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_d3863c12-5bb3-4999-8cbe-53ff3302917d">
                     <id root="d3863c12-5bb3-4999-8cbe-53ff3302917d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Cardiovascular Thrombotic Events</title>
                     <text>
                        <paragraph>Clinical trials of several COX-2  selective and nonselective NSAIDs  of upÂ <content styleCode="xmChange">to</content> three  years duration have  shown an increased risk of serious cardiovascular (CV) thrombotic events, including  myocardial infarction (MI) and stroke,  which can be fatal. Based on available data, it is unclear that the risk for CV thrombotic events is  similar for all NSAIDs. The relative increase in serious CV thrombotic events over baseline conferred by NSAID use appears to be similar in those  with and  without known CV disease or risk factors for CV disease.  However, patients  with known CV disease or risk factors had a higher absolute incidence of excess serious CV thrombotic events, due to their increased baseline rate. Some observational studies found that this increased risk of serious CV thrombotic events began as early as the first weeks of treatment. The increase in CV thrombotic risk has been observed most consistently at higher doses.<br/>
                           <br/>In the APC (Adenoma Prevention  with Celecoxib) trial, the hazard  ratio for the composite endpoint of cardiovascular death, MI, or stroke was  3.4 (95%  CI 1.4  to 8.5) for celecoxib 400 mg  twice daily and 2.8 (95% CI 1.1  to 7.2) with celecoxib 200 mg  twice daily compared to placebo. Cumulative rates for this composite endpoint over 3  years were 3% (20/671 subjects) and 2.5% (17/685 subjects),  respectively, compared to 0.9% (6/679 subjects)  with placebo treatment. The increases in both celecoxib dose groups versus placebo-treated patients  were mainly due to an increased incidence of  myocardial infarction [<content styleCode="italics">see <linkHtml href="#LINK_c3b28510-93cc-4660-a903-8a090301704c">Clinical Studies (14.6)</linkHtml>
                           </content>].<br/>
                           <br/>To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the  lowest effective dose for the shortest  duration possible.  Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even in the absence of previous CV symptoms. Patients should be informed about the symptoms of serious CV events and the steps to take if they  occur.<br/>
                           <br/>There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of  serious CV thrombotic events associated  with NSAID use. The concurrent use of aspirin and an NSAID, such as celecoxib, increases the risk of  serious gastrointestinal (GI) events [<content styleCode="italics">see <linkHtml href="#LINK_5069f2c7-1a91-4542-a9be-3aa4f8dbb0bc">Warnings and Precautions (5.2)</linkHtml>
                           </content>].<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Status</content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics"> Post</content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics"> Coronary</content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics"> Artery</content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics"> Bypass</content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics"> Graft</content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics"> (CABG)</content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics"> Surgery<br/>
                              </content>
                           </content>
                           <br/>Two large, controlled  clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10  to 14 days  following CABG  surgery found an increased incidence of myocardial infarction and stroke. NSAIDs are contraindicated in the setting of CABG [<content styleCode="italics">see <linkHtml href="#LINK_4e64c33b-fc94-493c-9ebc-d5f9c2eeeaa0">Contraindications (4)</linkHtml>
                           </content>].<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Post-MI</content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics"> Patients<br/>
                              </content>
                           </content>
                           <br/>Observational studies conducted in the Danish National Registry have demonstrated that patients treated  with NSAIDs in the  post-MI period were at increased risk of reinfarction, CV-related death, and all-cause mortality beginning in the first  week of treatment. In this same cohort, the incidence of death in the first  year post-MI  was 20 per 100 person years in NSAID-treated patients compared to 12 per 100 person years in non-NSAID exposed patients. Although the absolute rate of death declined  somewhat after the first year post-MI, the increased relative risk of death in NSAID users persisted over at least the next four  years of  follow-up.<br/>
                           <br/>Avoid the use of celecoxib in patients  with a recent MI unless the benefits are expected to  outweigh the risk of recurrent CV  thrombotic events. If celecoxib is used in patients  with a recent MI, monitor patients for signs of cardiac ischemia.</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_5069f2c7-1a91-4542-a9be-3aa4f8dbb0bc">
                     <id root="5069f2c7-1a91-4542-a9be-3aa4f8dbb0bc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Gastrointestinal Bleeding, Ulceration, and Perforation</title>
                     <text>
                        <paragraph>NSAIDs,  including celecoxib cause serious gastrointestinal (GI) adverse events  including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small  intestine, or large intestine,  which can be fatal. These serious adverse events can occur at any time,  with or  without warning  symptoms, in patients treated  with celecoxib. Only one in five patients  who develop a serious upper GI adverse event on NSAID therapy is symptomatic. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occurred in approximately 1% of patients treated for 3 to 6 months, and  in about 2% to 4% of patients treated for one year. However, even short-term NSAID therapy is not  without risk.<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Risk</content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics"> Factors</content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics"> for</content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics"> GI</content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics"> Bleeding,</content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics"> Ulceration,</content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics"> and</content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics"> Perforation<br/>
                              </content>
                           </content>
                           <br/>Patients  with a prior history of peptic ulcer disease and/or GI bleeding who used NSAIDs had a greater than 10-fold increased risk for developing a GI bleed compared to patients  without these risk factors. Other factors that increase the risk of GI bleeding in patients  treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants; or selective  serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. Most postmarketing reports of fatal GI events occurred in elderly or debilitated patients.  Additionally, patients  with advanced liver disease and/or coagulopathy are at increased risk for GI bleeding.<br/>
                           <br/>Complicated and  symptomatic ulcer rates  were 0.78% at nine months for all patients in the CLASS trial, and 2.19% for the  subgroup on  low-dose ASA. Patients 65  years of age and older had an incidence of 1.40% at nine months, 3.06% when also taking ASA [<content styleCode="italics">see <linkHtml href="#LINK_c3b28510-93cc-4660-a903-8a090301704c">Clinical Studies (14.6)</linkHtml>
                           </content>].<br/>
                           <content styleCode="bold">
                              <br/>Strategies to</content>
                           <content styleCode="bold"> Minimize the GI Risks in NSAID-treated patients:</content>
                        </paragraph>
                        <br/>
                        <list listType="unordered" styleCode="Disk">
                           <item>Use the  lowest effective dosage for the shortest possible duration.</item>
                           <item>Avoid administration of more than one NSAID at a time.</item>
                           <item>Avoid use in patients at higher risk unless benefits are expected to  outweigh the increased risk of bleeding. For such patients, as  well as those  with active GI bleeding, consider alternate therapies other than NSAIDs.</item>
                           <item>Remain alert for signs and  symptoms of GI ulceration and bleeding during NSAID therapy.</item>
                           <item>If a serious GI adverse event is  suspected, promptly initiate evaluation and treatment, and discontinue celecoxib until a serious GI adverse event is ruled out.</item>
                           <item>In the setting of concomitant use of low-dose aspirin for cardiac  prophylaxis, monitor patients more closely for evidence of GI bleeding [<content styleCode="italics">see </content>
                              <content styleCode="italics">
                                 <linkHtml href="#LINK_93869e4e-072e-4529-aef5-761fb3a6d1b1">Drug Interactions  (7)</linkHtml>
                              </content>].</item>
                        </list>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_123c45b9-a78a-40ef-ae49-d72c8d0bd6ba">
                     <id root="123c45b9-a78a-40ef-ae49-d72c8d0bd6ba"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Hepatotoxicity</title>
                     <text>
                        <paragraph>Elevations of ALT or AST (three or more times the upper limit of normal [ULN]) have been reported in approximately 1% of  NSAID-treated patients in  clinical trials. In  addition, rare, sometimes fatal, cases of severe hepatic  injury, including fulminant hepatitis, liver necrosis, and hepatic failure have been reported.<br/>
                           <br/>Elevations of ALT or AST (less than three times ULN) may occur in up to 15% of patients treated  with NSAIDs  including celecoxib.<br/>
                           <br/>In controlled clinical trials of celecoxib, the incidence of borderline elevations (greater than or equal to 1.2 times and less than 3 times the upper limit of normal) of liver associated enzymes  was 6% for celecoxib and 5% for placebo, and approximately 0.2% of patients taking celecoxib and 0.3% of patients taking placebo had notable elevations of ALT and AST.<br/>
                           <br/>Inform patients of the  warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, diarrhea, pruritus, jaundice, right upper quadrant tenderness, and âflu-likeâ symptoms). If clinical signs and symptoms consistent  with liver disease develop, or if  systemic manifestations occur (e.g., eosinophilia, rash, etc.), discontinue celecoxib  immediately, and perform a  clinical evaluation of the patient.</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_7a44f63e-a433-4488-8e48-4e737b9afdf8">
                     <id root="7a44f63e-a433-4488-8e48-4e737b9afdf8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Hypertension</title>
                     <text>
                        <paragraph>NSAIDs,  including celecoxib can lead to new onset of hypertension or  worsening of preexisting hypertension, either of  which may contribute to the increased incidence of CV events. Patients taking angiotensin converting enzyme (ACE) inhibitors, thiazide diuretics or loop diuretics may have impaired response to these therapies when taking NSAIDs [<content styleCode="italics">see <linkHtml href="#LINK_93869e4e-072e-4529-aef5-761fb3a6d1b1">Drug Interactions (7)</linkHtml>
                           </content>].<br/>
                           <br/>The rates of  hypertension from the CLASS trial in the celecoxib,Â ibuprofen and diclofenac-treated patients  were 2.4%, 4.2% and  2.5%, respectively [see <linkHtml href="#LINK_c3b28510-93cc-4660-a903-8a090301704c">Clinical Studies (14.6)</linkHtml>].<br/>
                           <br/>Monitor blood pressure (BP) during the initiation of NSAID treatment and throughout the course of therapy.</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_87f8faba-2740-4011-a06c-b2662ad92372">
                     <id root="87f8faba-2740-4011-a06c-b2662ad92372"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Heart Failure and Edema</title>
                     <text>
                        <paragraph>The Coxib and traditional NSAID Trialistsâ  Collaboration meta-analysisÂ <content styleCode="xmChange">of</content> randomized controlled trials demonstrated an approximately twoÂ­fold increase in  hospitalizations for heart failure in COX-2 selective-treated patients and nonselective NSAID-treated patients compared to placebo-treated patients. In a Danish National Registry study of patients  with heart failure, NSAID use increased the risk of MI, hospitalization  for heart failure, and death.<br/>
                           <br/>Additionally, fluid retention and edema have been observed in some patients treated  with NSAIDs. Use of celecoxib may blunt the  CV effects of several therapeutic agents used to treat these  medical conditions (e.g., diuretics,  ACE inhibitors, or angiotensin  receptor blockers [ARBs]) [<content styleCode="italics">see <linkHtml href="#LINK_93869e4e-072e-4529-aef5-761fb3a6d1b1">Drug Interactions (7)</linkHtml>
                           </content>].<br/>
                           <br/>In the CLASS study  [<content styleCode="italics">seeÂ </content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_c3b28510-93cc-4660-a903-8a090301704c">Clinical Studies (14.6)</linkHtml>
                           </content>], the Kaplan-Meier cumulative rates at 9 months of peripheral edema in patients on celecoxib 400 mg  twice daily (4-fold and 2-fold the recommended OA and RA doses, respectively), ibuprofen 800 mg three times daily and diclofenac 75 mg  twice daily were 4.5%, 6.9% and 4.7%,  respectively.<br/>
                           <br/>Avoid the use of celecoxib in patients  with severe heart failure unless the benefits are expected to  outweigh the risk of  worsening heart failure. If celecoxib is used in patients  with severe heart failure, monitor patients for signs of  worsening heart failure.</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_2ce69f4f-9899-4506-91c2-9d2771f1355f">
                     <id root="2ce69f4f-9899-4506-91c2-9d2771f1355f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Renal Toxicity and Hyperkalemia</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics"> Renal</content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics"> Toxicity<br/>
                              </content>
                           </content>
                           <br/>Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal  injury. <br/>
                           <br/>Renal toxicity has also been seen in patients in  whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood  flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those  with impaired renal function, dehydration, hypovolemia<content styleCode="bold">, </content>heart failure, liver  dysfunction, those taking diuretics, ACE-inhibitors or the ARBs, and the  elderly. Discontinuation of NSAID therapy is usually  followed by recovery to the pretreatment state.<br/>
                           <br/>No information is available from controlled clinical studies regarding the use of celecoxib in patients  with advanced renal disease. The renal effects of celecoxib may hasten the progression of renal dysfunction in patients  with preexisting renal disease.<br/>
                           <br/>Correct volume status in dehydrated or hypovolemic patients prior to initiating celecoxib. Monitor renal function in patients  with renal or hepatic impairment, heart failure, dehydration, or hypovolemia during use of celecoxib [<content styleCode="italics">see <linkHtml href="#LINK_93869e4e-072e-4529-aef5-761fb3a6d1b1">Drug Interactions (7)</linkHtml>
                           </content>]<content styleCode="italics">. </content>Avoid the use of celecoxib in patients  with advanced renal disease unless the benefits are expected to  outweigh the risk of  worsening renal function. If celecoxib is used in patients  with advanced renal disease, monitor patients for signs of  worsening renal function.<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Hyperkalemia<br/>
                              </content>
                           </content>
                           <br/>Increases in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs, even in some patients  without renal impairment. In patients  with normal renal function, these effects have been attributed to a hyporeninemic- hypoadosteronism state.</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_06dd8f73-061b-470b-a423-4a7f979e165b">
                     <id root="06dd8f73-061b-470b-a423-4a7f979e165b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Anaphylactic Reactions</title>
                     <text>
                        <paragraph>Celecoxib has been associated  with anaphylactic reactions in patients  with and without  known hypersensitivity to celecoxib and in patients  with aspirin sensitive asthma. Celecoxib is a sulfonamide and both NSAIDs and sulfonamides may cause allergic  type reactions including  anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible  people [seeÂ <content styleCode="italics">
                              <linkHtml href="#LINK_4e64c33b-fc94-493c-9ebc-d5f9c2eeeaa0">Contraindications (4)</linkHtml> and <linkHtml href="#LINK_3c3b0eff-1277-499f-bc25-a8f91329efe7">Warnings and Precautions (5.8)</linkHtml>
                           </content>].<br/>
                           <br/>Seek emergency help if any anaphylactic reaction occurs.</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_3c3b0eff-1277-499f-bc25-a8f91329efe7">
                     <id root="3c3b0eff-1277-499f-bc25-a8f91329efe7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Exacerbation of Asthma Related to Aspirin Sensitivity</title>
                     <text>
                        <paragraph>A subpopulation of patients  with asthma may have aspirin-sensitive asthma  which may include chronic rhinosinusitis complicated by  nasal polyps; severe, potentially fatal bronchospasm; and/or intolerance to aspirin and other NSAIDs. Because cross-reactivity  between aspirin and other NSAIDs has been reported in  such aspirin-sensitive patients, celecoxib is contraindicated in patients  with this form of aspirin sensitivity [<content styleCode="italics">see <linkHtml href="#LINK_4e64c33b-fc94-493c-9ebc-d5f9c2eeeaa0">Contraindications (4)</linkHtml>
                           </content>]. When celecoxib is used in patients  with preexisting asthma  (without known aspirin  sensitivity), monitor patients for changes in the signs and symptoms of asthma.</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_5c76fc34-dcf3-40cc-b188-315fbbb7ff33">
                     <id root="5c76fc34-dcf3-40cc-b188-315fbbb7ff33"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Serious Skin Reactions</title>
                     <text>
                        <paragraph>Serious skin reactions have occurred  following treatment  with celecoxib, including  erythema multiforme, exfoliative dermatitis,  Stevens-Johnson syndrome (SJS),  toxic epidermal  necrolysis (TEN), drug reaction  with eosinophilia and  systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP). These serious events may occur  without warning and can be fatal.<br/>
                           <br/>Inform patients about the signs and  symptoms of serious skin reactions, and to discontinue the use of celecoxib at the first appearance of skin rash or any other sign of  hypersensitivity. Celecoxib is contraindicated in patients  with previous serious skin reactions  to NSAIDs [<content styleCode="italics">see </content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_4e64c33b-fc94-493c-9ebc-d5f9c2eeeaa0">Contraindications  (4)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_4785b1f6-62b6-4f3b-86f3-1c6d5e6adb2d">
                     <id root="4785b1f6-62b6-4f3b-86f3-1c6d5e6adb2d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10 Premature Closure of Fetal Ductus Arteriosus</title>
                     <text>
                        <paragraph>Celecoxib may cause premature closure of the ductus arteriosus. Avoid use of NSAIDs, including celecoxib,Â in pregnant  women starting at 30  weeks of gestation (third trimester) [<content styleCode="italics">see <linkHtml href="#LINK_f3aec266-21a6-4ac8-936c-cb2499eb89de">Use in Specific  Populations (8.1)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c567e811-3129-4615-9802-6c822560bbcc">
                     <id root="c567e811-3129-4615-9802-6c822560bbcc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.11 Hematological Toxicity</title>
                     <text>
                        <paragraph>Anemia has occurred in NSAID-treated patients. This may be due to occult or gross blood loss, fluid retention, or an incompletely described effect on erythropoiesis. If a patient treated  with celecoxib has any signs or  symptoms of anemia, monitor hemoglobin or hematocrit.<br/>
                           <br/>In controlled clinical trials the incidence of anemia  was 0.6%  with celecoxib and 0.4%  with placebo. Patients on long-term treatment  with celecoxib should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of anemia or blood loss.<br/>
                           <br/>NSAIDs,  including celecoxib,Â may increase the risk of bleeding events. Co-morbid conditions such as coagulation disorders or concomitant use of  warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. Monitor these patients for signs of bleeding [<content styleCode="italics">see <linkHtml href="#LINK_93869e4e-072e-4529-aef5-761fb3a6d1b1">Drug Interactions  (7)</linkHtml>
                           </content> ].</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_dd021e2d-c6f0-4cd4-8414-527f3c2f9b7f">
                     <id root="dd021e2d-c6f0-4cd4-8414-527f3c2f9b7f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.12 Masking of Inflammation and Fever</title>
                     <text>
                        <paragraph>The pharmacological activity of celecoxib in reducing inflammation, and possibly fever, may diminish the utility of diagnostic signs in detecting infections.</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_5830b273-2160-48ff-8fe6-0d9824863522">
                     <id root="5830b273-2160-48ff-8fe6-0d9824863522"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.13 Laboratory Monitoring</title>
                     <text>
                        <paragraph>Because serious GI bleeding, hepatotoxicity, and renal injury can occur  without warning symptoms or signs, consider monitoring patients on long-term NSAID treatment  with a CBC and a chemistry profile periodically [<content styleCode="italics">see <linkHtml href="#LINK_5069f2c7-1a91-4542-a9be-3aa4f8dbb0bc">Warnings and Precautions (5.2</linkHtml>, <linkHtml href="#LINK_123c45b9-a78a-40ef-ae49-d72c8d0bd6ba">5.3</linkHtml>, <linkHtml href="#LINK_2ce69f4f-9899-4506-91c2-9d2771f1355f">5.6)</linkHtml>
                           </content>].<br/>
                           <br/>In controlled clinical trials,  elevated BUN occurred more frequently in patients receiving celecoxib compared  with patients on placebo. This laboratory abnormality  was also seen in patients  who received comparator NSAIDs in these studies. The clinical significance of this abnormality has not been established.</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_94d6f61a-0190-4477-979c-9825f2a095d0">
                     <id root="94d6f61a-0190-4477-979c-9825f2a095d0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.14 Disseminated Intravascular Coagulation (DIC)</title>
                     <text>
                        <paragraph>Because of the risk of  disseminated intravascular coagulation  with use of celecoxib in pediatric patients  with systemic onset  JRA, monitor patients for signs and  symptoms of abnormal clotting or bleeding, and inform patients and their caregivers to report symptoms as soon as possible.</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_ef9fb1b1-2af0-467d-83a9-5106ce454cfc">
               <id root="b4225573-7cb7-4d3e-9f3c-0bfe3ba42c7c"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6. ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The  following adverse reactions are discussed in  greater detail in other sections of the labeling:</paragraph>
                  <br/>
                  <list listType="unordered" styleCode="Disk">
                     <item> Cardiovascular Thrombotic Events [<content styleCode="italics">see </content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_d3863c12-5bb3-4999-8cbe-53ff3302917d">Warnings and Precautions  (5.1)</linkHtml>
                        </content>]</item>
                     <item>GI Bleeding, Ulceration and Perforation [<content styleCode="italics">see <content styleCode="italics">
                              <linkHtml href="#LINK_5069f2c7-1a91-4542-a9be-3aa4f8dbb0bc">Warnings and Precautions (5.2)</linkHtml>
                           </content>
                        </content>]</item>
                     <item>Hepatotoxicity [<content styleCode="italics">see <content styleCode="italics">
                              <linkHtml href="#LINK_123c45b9-a78a-40ef-ae49-d72c8d0bd6ba">Warnings  and Precautions (5.3)</linkHtml>
                           </content>
                        </content>]</item>
                     <item>Hypertension  [<content styleCode="italics">seeÂ </content>
                        <content styleCode="italics">
                           <content styleCode="italics">
                              <linkHtml href="#LINK_7a44f63e-a433-4488-8e48-4e737b9afdf8">Warnings and Precautions (5.4)</linkHtml>
                           </content>
                        </content>]</item>
                     <item>Heart Failure and Edema [<content styleCode="italics">see <content styleCode="italics">
                              <linkHtml href="#LINK_87f8faba-2740-4011-a06c-b2662ad92372">Warnings and Precautions (5.5)</linkHtml>
                           </content>
                        </content>]</item>
                     <item>Renal Toxicity and Hyperkalemia [<content styleCode="italics">see <content styleCode="italics">
                              <linkHtml href="#LINK_2ce69f4f-9899-4506-91c2-9d2771f1355f">Warnings and Precautions (5.6)</linkHtml>
                           </content>
                        </content>]</item>
                     <item> Anaphylactic Reactions [<content styleCode="italics">see <content styleCode="italics">
                              <linkHtml href="#LINK_06dd8f73-061b-470b-a423-4a7f979e165b">Warnings and Precautions (5.7)</linkHtml>
                           </content>
                        </content>]</item>
                     <item>Serious Skin Reactions [<content styleCode="italics">see <content styleCode="italics">
                              <linkHtml href="#LINK_5c76fc34-dcf3-40cc-b188-315fbbb7ff33">Warnings and Precautions (5.9)</linkHtml>
                           </content>
                        </content>]</item>
                     <item>Hematologic Toxicity  [<content styleCode="italics">seeÂ </content>
                        <content styleCode="italics">
                           <content styleCode="italics">
                              <linkHtml href="#LINK_c567e811-3129-4615-9802-6c822560bbcc">Warnings and Precautions (5.11)</linkHtml>
                           </content>
                        </content>]</item>
                  </list>
               </text>
               <effectiveTime value="20170620"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions in arthritis trials (&gt;2% and &gt;placebo) are: abdominal pain, diarrhea,  dyspepsia, flatulence, peripheral edema, accidental  injury, dizziness,  pharyngitis, rhinitis, sinusitis, upper  respiratory tract infection, rash <linkHtml href="#LINK_e87c3e20-ab8a-42f0-b0e5-23bb74f2a37f">(6.1)</linkHtml>.<br/>
                           <content styleCode="bold">
                              <br/>To report SUSPECTED ADVERSE REACTIONS, contact Cambridge Therapeutic Technologies at 1-844-810-0004 or FDA at 1-800-FDA-1088 or <content styleCode="underline">www.fda.gov/medwatch</content>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_e87c3e20-ab8a-42f0-b0e5-23bb74f2a37f">
                     <id root="e87c3e20-ab8a-42f0-b0e5-23bb74f2a37f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under  widely varying conditions, adverse reaction rates observed in the clinical trials of a  drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does,  however, provide a basis for  identifying the adverse events that appear to be  related to drug use and for approximating rates.<br/>
                           <br/>Of the celecoxib-treated patients in the pre-marketing controlled clinical trials, approximately 4,250 were patients  with OA, approximately 2,100  were patients  with RA, and approximately 1,050  were patients  with post-surgical pain. More than 8,500 patients received a total daily dose of celecoxib of 200 mg (100 mg  twice daily or 200 mg once  daily) or more, including more than 400 treated at 800 mg (400 mg  twice daily). Approximately 3,900 patients received celecoxib at these doses for 6 months or more; approximately 2,300 of these have received it for 1 year or more and 124 of these have received it for 2  years or more.<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Pre-marketing Controlled Arthritis Trials<br/>
                              </content>
                           </content>
                           <br/>Table 1 lists all  adverse events, regardless of  causality, occurring in â¥2% of patients receiving celecoxib from 12 controlled studies conducted in patients  with OA or RA that included a placebo and/or a positive control group. Since these 12 trials  were of different durations, and patients in the trials may not have been exposed for the same duration of time, these percentages do not capture cumulative rates of occurrence.</paragraph>
                        <table>
                           <caption>Table 1: Adverse Events Occurring in &gt;2% of Celecoxib Patients from Pre-marketing Controlled Arthritis Trials</caption>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <tfoot>
                              <tr>
                                 <td align="justify" colspan="6">Â CBX = Celecoxib 100 to 200 mg twice daily or 200 mg once daily; <br/>NAP = Naproxen 500 mg twice daily; <br/>DCF = Diclofenac 75 mg twice daily; <br/>IBU = Ibuprofen 800 mg three times daily. <br/>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â Â <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">CBX</content>
                                    <br/>N=4146<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">Placebo</content>
                                    <br/>N=1864<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">NAP</content>
                                    <br/>N=1366<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">DCF</content>
                                    <br/>N=387<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">IBU </content>
                                    <br/>N=345<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold">Â Gastrointestinal </content>
                                    <br/>Â Â Â Â  Abdominal Pain<br/>Â Â Â Â  Diarrhea<br/>Â Â Â Â  Dyspepsia<br/>Â Â Â Â  Flatulence <br/>Â Â Â Â  Nausea<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â Â <br/>4.1%<br/>5.6% <br/>8.8% <br/>2.2% <br/>3.5%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â Â <br/>2.8% <br/>3.8%<br/>Â 6.2% <br/>1% <br/>4.2%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â Â <br/>7.7%<br/>Â 5.3% <br/>12.2%<br/>Â 3.6%<br/>6%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â Â <br/>9%<br/>9.3%<br/>10.9%<br/>4.1%<br/>3.4%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â Â <br/>9%<br/>5.8%<br/>12.8%<br/>3.5%<br/>6.7%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold">Â Body as a whole</content>
                                    <br/>Â Â Â Â  Back Pain <br/>Â Â Â Â  Peripheral Edema<br/>Â Â Â Â  Injury-Accidental<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â Â <br/>2.8%<br/>2.1%<br/>2.9%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â Â <br/>3.6%<br/>1.1%<br/>2.3%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â Â <br/>2.2%<br/>2.1%<br/>3%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â Â <br/>2.6%<br/>1%<br/>2.6%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â Â <br/>0.9%<br/>3.5%<br/>3.2%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold">Â Central, Peripheral Nervous system</content>
                                    <br/>Â Â Â Â  Dizziness<br/>Â Â Â Â  Headache<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â Â <br/>2%<br/>15.8%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â Â <br/>1.7%<br/>20.2%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â Â <br/>2.6%<br/>14.5%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â Â <br/>1.3%<br/>15.5%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â Â <br/>2.3%<br/>15.4%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold">Â Psychiatric</content>
                                    <br/>Â Â Â Â  Insomnia<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â Â <br/>2.3%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â Â <br/>2.3%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â Â <br/>2.9%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â Â <br/>1.3%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â Â <br/>1.4%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold">Â Respiratory </content>
                                    <br/>Â Â Â Â  Pharyngitis <br/>Â Â Â Â  Rhinitis <br/>Â Â Â Â  Sinusitis <br/>Â Â Â Â  Upper Respiratory Infection<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â Â <br/>2.3%<br/>2%<br/>5%<br/>8.1%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â Â <br/>1.1%<br/>1.3%<br/>4.3%<br/>6.7%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â Â <br/>1.7%<br/>2.4%<br/>4%<br/>9.9%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â Â <br/>1.6%<br/>2.3%<br/>5.4%<br/>9.8%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â Â <br/>2.6%<br/>0.6%<br/>5.8%<br/>9.9%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold">Â Skin </content>
                                    <br/>Â Â Â Â  Rash<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â Â <br/>2.2%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â Â <br/>2.1%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â Â <br/>2.1%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â Â <br/>1.3%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â Â <br/>1.2%<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In placebo- or active-controlled clinical trials, the discontinuation rate due to adverse events was 7.1% for patients receiving celecoxib and 6.1% for patients receiving placebo. Among the most common reasons for discontinuation due to adverse events in the celecoxib treatment groups were dyspepsia and abdominal pain (cited as reasons for discontinuation in 0.8% and 0.7% of celecoxib patients, respectively). Among patients receiving placebo, 0.6% discontinued due to dyspepsia and 0.6% withdrew due to abdominal pain.<br/>
                           <content styleCode="bold">
                              <br/>The following adverse reactions occurred in 0.1 to 1.9% of patients treated with celecoxib (100 to 200 mg twice daily or 200 mg once daily):<br/>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Gastrointestinal: </content>
                           </content>Constipation, diverticulitis, dysphagia, eructation, esophagitis, gastritis, gastroenteritis, gastroesophageal reflux, hemorrhoids, hiatal hernia, melena, dry mouth, stomatitis, tenesmus, vomiting<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Cardiovascular:</content>
                           </content> Aggravated hypertension, angina pectoris, coronary artery disorder, myocardial infarction<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>General:</content>
                           </content> Hypersensitivity, allergic reaction, chest pain, cyst NOS, edema generalized, face edema, fatigue, fever, hot flushes, influenza-like symptoms, pain, peripheral pain<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Central, peripheral nervous system:</content>
                           </content>Â  Leg cramps, hypertonia, hypoesthesia, migraine, paresthesia, vertigo<content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>
                              </content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Hearing and vestibular: </content>
                           </content>Deafness, tinnitus<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Heart rate and rhythm:</content>
                           </content> Palpitation, tachycardia<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Liver and biliary:</content>
                           </content> Hepatic enzyme increased (including SGOT increased, SGPT increased)<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Metabolic and nutritional:</content>
                           </content> BUN increased, CPK increased, hypercholesterolemia, hyperglycemia, hypokalemia, NPN increased, creatinine increased, alkaline phosphatase increased, weight increased<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Musculoskeletal: </content>
                           </content>Arthralgia, arthrosis, myalgia, synovitis, tendinitis<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Platelets (bleeding or clotting):</content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics">Â </content>
                           </content>Ecchymosis, epistaxis, thrombocythemia,<content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>
                              </content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Psychiatric:</content>
                           </content> Anorexia, anxiety, appetite increased, depression, nervousness, somnolence<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Hemic:</content>
                           </content> Anemia<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Respiratory:</content>
                           </content> Bronchitis, bronchospasm, bronchospasm aggravated, cough, dyspnea, laryngitis, pneumonia<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Skin and appendages:</content>
                           </content> Alopecia, dermatitis, photosensitivity reaction, pruritus, rash erythematous, rash maculopapular, skin disorder, skin dry, sweating increased, urticaria<content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>
                              </content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Application site disorders:</content>
                           </content> Cellulitis, dermatitis contact<content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>
                              </content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Urinary:</content>
                           </content> Albuminuria, cystitis, dysuria, hematuria, micturition frequency, renal calculus <br/>
                           <content styleCode="bold">
                              <br/>The following serious adverse events (causality not evaluated) occurred in &lt;0.1% of patients:<br/>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Cardiovascular:</content>
                           </content> Syncope, congestive heart failure, ventricular fibrillation, pulmonary embolism, cerebrovascular accident, peripheral gangrene, thrombophlebitis <br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Gastrointestinal:</content>
                           </content> Intestinal obstruction, intestinal perforation, gastrointestinal bleeding, colitis with bleeding, esophageal perforation, pancreatitis, ileus<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>General:</content>
                           </content> Sepsis, sudden death<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Liver and biliary:</content>
                           </content> Cholelithiasis<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Hemic and lymphatic: </content>
                           </content>Thrombocytopenia<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Nervous:</content>
                           </content> Ataxia, suicide <content styleCode="italics">[see <linkHtml href="#LINK_93869e4e-072e-4529-aef5-761fb3a6d1b1">Drug Interactions (7.1)</linkHtml>]<br/>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Renal:</content>
                           </content> Acute renal failure<br/>
                           <content styleCode="bold">
                              <br/>The Celecoxib Long-Term Arthritis Safety Study [see <linkHtml href="#LINK_c3b28510-93cc-4660-a903-8a090301704c">Special Studies  (14.6)</linkHtml>]<br/>
                           </content>
                           <content styleCode="italics">
                              <br/>Hematological Events: </content>The incidence of clinically significant decreases in hemoglobin (&gt;2 g/dL) was lower in patients on celecoxib 400 mg twice daily (0.5%) compared to patients on either diclofenac 75 mg twice daily (1.3%) or ibuprofen 800 mg three times daily 1.9%. The lower incidence of events with celecoxib was maintained with or without aspirin use [<content styleCode="italics">see <linkHtml href="#LINK_16202f21-e009-4128-b5c5-60dccddbe86e">Clinical Pharmacology (12.2)</linkHtml>
                           </content>].<br/>
                           <content styleCode="italics">
                              <br/>Withdrawals/Serious Adverse Events: </content>Kaplan-Meier cumulative rates at 9 months for withdrawals due to adverse events for celecoxib, diclofenac and ibuprofen were 24%, 29%, and 26%, respectively. Rates for serious adverse events (i.e., causing hospitalization or felt to be life-threatening or otherwise medically significant), regardless of causality, were not different across treatment groups (8%, 7%, and 8%, respectively). <br/>
                           <content styleCode="bold">
                              <br/>
                              <content styleCode="italics">Juvenile Rheumatoid Arthritis Study</content>
                              <br/>
                           </content>
                           <br/>In a 12-week, double-blind, active-controlled study, 242 JRA patients 2 years to 17 years of age were treated with celecoxib or naproxen; 77 JRA patients were treated with celecoxib 3 mg/kg twice daily, 82 patients were treated with celecoxib 6 mg/kg twice daily, and 83 patients were treated with naproxen 7.5 mg/kg twice daily. The most commonly occurring (â¥5%) adverse events in celecoxib treated patients were headache, fever (pyrexia), upper abdominal pain, cough, nasopharyngitis, abdominal pain, nausea, arthralgia, diarrhea and vomiting. The most commonly occurring (â¥5%) adverse experiences for naproxen-treated patients were headache, nausea, vomiting, fever, upper abdominal pain, diarrhea, cough, abdominal pain, and dizziness (Table 2). Compared with naproxen, celecoxib at doses of 3 and 6 mg/kg twice daily had no observable deleterious effect on growth and development during the course of the 12-week double-blind study. There was no substantial difference in the number of clinical exacerbations of uveitis or systemic features of JRA among treatment groups.<br/>
                           <br/>In a 12-week, open-label extension of the double-blind study described above, 202 JRA patients were treated with celecoxib 6 mg/kg twice daily. The incidence of adverse events was similar to that observed during the double-blind study; no unexpected adverse events of clinical importance emerged.</paragraph>
                        <table>
                           <caption>Table 2: Adverse Events Occurring in â¥5% of JRA Patients in Any Treatment Group, by System Organ Class (% of patients with events) 
			</caption>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <tfoot>
                              <tr>
                                 <td align="justify" colspan="4">Â * Abnormal laboratory tests, which include: Prolonged activated partial thromboplastin time, Bacteriuria NOS present, Blood creatine phosphokinase increased, Blood culture positive, Blood glucose increased, Blood pressure increased, Blood uric acid increased, Hematocrit decreased, Hematuria present, Hemoglobin decreased, Liver function tests NOS abnormal, Proteinuria present, Transaminase NOS increased, Urine analysis abnormal NOS <br/>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td valign="top" rowspan="2" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold">Â System Organ Class</content>
                                    <br/>Â Preferred Term<br/>
                                 </td>
                                 <td align="center" valign="top" colspan="3" styleCode="     Rrule     ">Â <content styleCode="bold">All Doses Twice Daily</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold">Celecoxib </content>
                                    <br/>
                                    <content styleCode="bold">3 mg/kg </content>
                                    <br/>
                                    <content styleCode="bold">N=77</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">Celecoxib</content>
                                    <br/>
                                    <content styleCode="bold">6 mg/kg </content>
                                    <br/>
                                    <content styleCode="bold">N=82</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">Naproxen</content>
                                    <br/>
                                    <content styleCode="bold">7.5 mg/kg </content>
                                    <br/>
                                    <content styleCode="bold">N=83</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold">Â Any Event </content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">64</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">70</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">72</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold">Â Eye Disorders</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">5</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">5</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">5</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold">Â Gastrointestinal</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">26</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">24</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">36</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â Â Â Â Â  Abdominal pain NOS <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 4<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 7<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 7<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â Â Â Â Â  Abdominal pain upper<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 8<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 6<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 10<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â Â Â Â Â  Vomiting NOS<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 3<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 6<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 11<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â Â Â Â Â  Diarrhea NOS<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 5<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 4<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 8<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â Â Â Â Â  Nausea<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 7<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 4<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 11<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold">Â General</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">13</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">11</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">18</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â Â Â Â Â  Pyrexia<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 8<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 9<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 11<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold">Â Infections</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">25</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">20</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">27</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â Â Â Â Â  Nasopharyngitis<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 5<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 6<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 5<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold">Â Injury and Poisoning</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">4</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">6</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">5</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold">Â Investigations*</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">3</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">11</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">7</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold">Â Musculoskeletal</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">8</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">10</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">17</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â Â Â Â Â  Arthralgia<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 3<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 7<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 4<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold">Â Nervous System</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">17</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">11</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">21</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â Â Â Â Â  Headache NOS<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 13<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 10<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 16<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â Â Â Â Â  Dizziness (excl vertigo)<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 1<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 1<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 7<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold">Â Respiratory</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">8</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">15</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">15</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â Â Â Â Â  Cough<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 7<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 7<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 8<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold">Â Skin &amp; Subcutaneous</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">10</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">7</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">18</content>
                                    <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold">Other Pre-Approval Studies<br/>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Adverse Events from Ankylosing Spondylitis Studies</content>
                           </content>
                           <content styleCode="italics">: </content>A total of 378 patients were treated with celecoxib in placebo- and active-controlled AS studies. Doses up to 400 mg once daily were studied. The types of adverse events reported in the AS studies were similar to those reported in the OA/RA studies. <br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Adverse Events from Analgesia and Dysmenorrhea Studies: </content>
                           </content>Approximately 1,700 patients were treated with celecoxib in analgesia and dysmenorrhea studies. All patients in post-oral surgery pain studies received a single dose of study medication. Doses up to 600 mg/day of celecoxib were studied in primary dysmenorrhea and post-orthopedic surgery pain studies. The types of adverse events in the analgesia and dysmenorrhea studies were similar to those reported in arthritis studies. The only additional adverse event reported was post-dental extraction alveolar osteitis (dry socket) in the post-oral surgery pain studies. <br/>
                           <content styleCode="bold">
                              <br/>The APC and PreSAP Trials <br/>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Adverse reactions from long-term, placebo-controlled polyp prevention studies</content>
                           </content>
                           <content styleCode="bold">: </content>Exposure to celecoxib in the APC and PreSAP trials was 400 to 800 mg daily for up to 3 years [<content styleCode="italics">see <linkHtml href="#LINK_c3b28510-93cc-4660-a903-8a090301704c">Special Studies Adenomatous Polyp Prevention Studies (14.6)</linkHtml>
                           </content>].<br/>
                           <br/>Some adverse reactions occurred in higher percentages of patients than in the arthritis pre-marketing trials (treatment durations up to 12 weeks; see <content styleCode="italics">Adverse events from </content>celecoxib<content styleCode="italics"> pre-marketing controlled arthritis trials</content>, above). The adverse reactions for which these differences in patients treated with celecoxib were greater as compared to the arthritis pre-marketing trials were as follows:</paragraph>
                        <table>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td align="center" valign="top" styleCode="    Lrule          Rrule     ">Â Â <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">Celecoxib </content>
                                    <br/>
                                    <content styleCode="bold">(400 to 800 mg daily)</content>
                                    <br/>
                                    <content styleCode="bold">
                                       <content styleCode="underline">N = 2285</content>
                                    </content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold">Placebo</content>
                                    <br/>
                                    <content styleCode="bold">
                                       <content styleCode="underline">Â N=1303</content>
                                    </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â Â Diarrhea<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 10.5%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 7%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â Â Gastroesophageal reflux disease<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 4.7%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 3.1%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â Â Nausea<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 6.8%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 5.3%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â Â Vomiting<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 3.2%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 2.1%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â Â Dyspnea<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 2.8%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 1.6%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â Â Hypertension<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 12.5%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 9.8%<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" valign="top" styleCode="    Lrule          Rrule     ">Â Â Nephrolithiasis<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 2.1%<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 0.8%<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The following additional adverse reactions occurred in â¥0.1% and &lt;1% of patients taking celecoxib, at an incidence greater than placebo in the long-term polyp prevention studies, and were either not reported during the controlled arthritis pre-marketing trials or occurred with greater frequency in the long-term, placebo-controlled polyp prevention studies: <br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Nervous system disorders: </content>
                           </content>Cerebral infarction<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Eye disorders: </content>
                           </content>Vitreous floaters, conjunctival hemorrhage<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Ear and labyrinth: </content>
                           </content>Labyrinthitis<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Cardiac disorders: </content>
                           </content>Angina unstable, aortic valve incompetence, coronary artery atherosclerosis, sinus bradycardia, ventricular hypertrophy<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Vascular disorders: </content>
                           </content>Deep vein thrombosis<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Reproductive system and breast disorders: </content>
                           </content>Ovarian cyst<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Investigations: </content>
                           </content>Blood potassium increased, blood sodium increased, blood testosterone decreased<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Injury, poisoning and procedural c</content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics">omplications</content>
                              <content styleCode="italics">:</content>
                           </content> Epicondylitis, tendon rupture </paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_491ffbd7-d737-4c55-9e16-68233ae7a95f">
                     <id root="491ffbd7-d737-4c55-9e16-68233ae7a95f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The  following adverse reactions have been identified during post approval use of celecoxib. Because these reactions are reported voluntarily from a population of uncertain size, it is not  always possible to reliably estimate their frequency or establish a causal relationship to drug exposure<br/>
                           <br/>
                           <content styleCode="italics">
                              <content styleCode="bold">Cardiovascular</content>
                           </content>
                           <content styleCode="italics">
                              <content styleCode="bold">: </content>
                           </content>Vasculitis, deep venous thrombosis<br/>
                           <br/>
                           <content styleCode="italics">
                              <content styleCode="bold">General: </content>
                           </content>Anaphylactoid reaction, angioedema<br/>
                           <br/>
                           <content styleCode="bold">
                              <content styleCode="italics">Liver and biliary</content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics">: </content>
                           </content>Liver necrosis, hepatitis, jaundice, hepatic failure<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Hemic and lymphatic</content>
                           </content>
                           <content styleCode="bold">:</content> Agranulocytosis, aplastic anemia, pancytopenia, leucopenia<br/>
                           <br/>
                           <content styleCode="bold">
                              <content styleCode="italics">Metabolic: </content>
                           </content>Hypoglycemia, hyponatremia<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Nervous</content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics">: </content>
                           </content>Aseptic meningitis, ageusia, anosmia, fatal intracranial hemorrhage<br/>
                           <br/>
                           <content styleCode="italics">
                              <content styleCode="bold">Renal</content>
                           </content>
                           <content styleCode="italics">
                              <content styleCode="bold">: </content>
                           </content>Interstitial nephritis</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_93869e4e-072e-4529-aef5-761fb3a6d1b1">
               <id root="93869e4e-072e-4529-aef5-761fb3a6d1b1"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7. DRUG INTERACTIONS</title>
               <text>
                  <paragraph>See Table 3 for  clinically significant drug interactions  with celecoxib.</paragraph>
                  <table>
                     <caption>Table 3: Clinically Significant Drug Interactions with Celecoxib</caption>
                     <col/>
                     <col/>
                     <tbody>
                        <tr>
                           <td valign="top" colspan="2" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold"> Â Drugs</content>
                              <content styleCode="bold"> That</content>
                              <content styleCode="bold"> Interfere w</content>
                              <content styleCode="bold">ith  Hemostasis</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="italics">Clinical  Impact:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode="     Rrule     ">Â <list listType="unordered" styleCode="Disk">
                                 <item>Celecoxib and anticoagulants such as  warfarin have a synergistic effect on bleeding. The concomitant use of Celecoxib and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone.</item>
                                 <item>Serotonin release by platelets  plays an important  role in hemostasis. Case-control and cohort epidemiological studies  showed that concomitant use of drugs that interfere  with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="italics">Intervention:</content>
                              <br/>
                           </td>
                           <td align="justify" valign="top" styleCode="     Rrule     ">Â Monitor patients  with concomitant use of celecoxib  with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [<content styleCode="italics">see </content>
                              <content styleCode="italics">
                                 <linkHtml href="#LINK_c567e811-3129-4615-9802-6c822560bbcc">Warnings and Precautions  (5.11)</linkHtml>
                              </content>].<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" colspan="2" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold"> Â Aspirin</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="italics">Clinical  Impact:</content>
                              <br/>
                           </td>
                           <td align="justify" valign="top" styleCode="     Rrule     ">Â Controlled  clinical studies  showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone. In a clinical  study, the concomitant use of an NSAID and aspirin  was associated  with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone [<content styleCode="italics">see <content styleCode="italics">
                                    <linkHtml href="#LINK_5069f2c7-1a91-4542-a9be-3aa4f8dbb0bc">Warnings and Precautions (5.2)</linkHtml>
                                 </content>
                              </content>].<br/>In  two studies in healthy volunteers, and in patients  with osteoarthritis and established heart disease  respectively, celecoxib (200 to 400 mg daily) has demonstrated a lack of interference  with the cardioprotective antiplatelet effect of aspirin (100 to 325 mg).<br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="italics">Intervention:</content>
                              <br/>
                           </td>
                           <td align="justify" valign="top" styleCode="     Rrule     ">Â Concomitant use of celecoxib and analgesic doses of aspirin is  not generally recommended because of the increased risk of bleeding [<content styleCode="italics">see <content styleCode="italics">
                                    <linkHtml href="#LINK_c567e811-3129-4615-9802-6c822560bbcc">Warnings and Precautions (5.11)</linkHtml>
                                 </content>
                              </content>].<br/>Celecoxib is not a substitute for low dose aspirin for cardiovascular protection.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" colspan="2" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold"> Â ACE</content>
                              <content styleCode="bold"> Inhibitors,</content>
                              <content styleCode="bold"> Angiotensin</content>
                              <content styleCode="bold"> Receptor</content>
                              <content styleCode="bold"> Blockers,</content>
                              <content styleCode="bold"> and</content>
                              <content styleCode="bold"> Beta-Blockers</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="italics">Clinical  Impact:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode="     Rrule     ">Â <list listType="unordered" styleCode="Disk">
                                 <item>NSAIDs may diminish the antihypertensive effect of angiotensin converting  enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers (including propranolol).</item>
                                 <item>In patients  who are  elderly, volume-depleted (including those on diuretic therapy), or  have renal impairment, co-administration of an NSAID  with ACE inhibitors or ARBs may result in deterioration of renal function,  including possible acute renal failure. These effects are usually reversible.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="italics">Intervention:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode="     Rrule     ">Â <list listType="unordered" styleCode="Disk">
                                 <item>During concomitant use of celecoxib and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained.</item>
                                 <item>During concomitant use of celecoxib and ACE-inhibitors or ARBs in patients  who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function [<content styleCode="italics">see <content styleCode="italics">
                                          <linkHtml href="#LINK_2ce69f4f-9899-4506-91c2-9d2771f1355f">Warnings and Precautions (5.6)</linkHtml>
                                       </content>
                                    </content>]<content styleCode="italics">.</content>
                                 </item>
                                 <item>When these drugs are administered  concomitantly, patients should be adequately hydrated. Assess renal function at the beginning of the concomitant treatment and periodically thereafter.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" colspan="2" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold"> Â Diuretics</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="italics">Clinical  Impact:</content>
                              <br/>
                           </td>
                           <td align="justify" valign="top" styleCode="     Rrule     ">Â Clinical studies, as  well as post-marketing observations,  showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. This effect has been attributed to the NSAID inhibition of renal prostaglandin  synthesis.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="italics">Intervention:</content>
                              <br/>
                           </td>
                           <td align="justify" valign="top" styleCode="     Rrule     ">Â During concomitant use of celecoxib  with diuretics, observe patients for signs of  worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [<content styleCode="italics">see </content>
                              <content styleCode="italics">
                                 <linkHtml href="#LINK_2ce69f4f-9899-4506-91c2-9d2771f1355f">Warnings and Precautions  (5.6)</linkHtml>
                              </content>].<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" colspan="2" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold"> Â Digoxin</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="italics">Clinical  Impact:</content>
                              <br/>
                           </td>
                           <td align="justify" valign="top" styleCode="     Rrule     ">Â The concomitant use of Celecoxib  with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="italics">Intervention:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode="     Rrule     ">Â During concomitant use of celecoxib and digoxin, monitor serum digoxin levels.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" colspan="2" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold"> Â Lithium</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="italics">Clinical  Impact:</content>
                              <br/>
                           </td>
                           <td align="justify" valign="top" styleCode="     Rrule     ">Â NSAIDs have produced elevations in plasma  lithium levels and reductions in renal lithium clearance<content styleCode="italics">. </content>The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%.  This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="italics">Intervention:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode="     Rrule     ">Â During concomitant use of celecoxib and lithium, monitor patients for signs of  lithium toxicity.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" colspan="2" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold"> Â Methotrexate</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="italics">Clinical  Impact:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode="     Rrule     ">Â Concomitant use of NSAIDs and methotrexate may  increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal  dysfunction).<br/>Celecoxib has no effect on  methotrexate pharmacokinetics.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="italics">Intervention:</content>
                              <br/>
                           </td>
                           <td align="justify" valign="top" styleCode="     Rrule     ">Â During concomitant use of celecoxib and methotrexate, monitor patients for methotrexate toxicity.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" colspan="2" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold"> Â Cyclosporine</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="italics">Clinical  Impact:</content>
                              <br/>
                           </td>
                           <td align="justify" valign="top" styleCode="     Rrule     ">Â Concomitant use of celecoxib and  cyclosporine may increase cyclosporineâs  nephrotoxicity.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="italics">Intervention:</content>
                              <br/>
                           </td>
                           <td align="justify" valign="top" styleCode="     Rrule     ">Â During concomitant use of celecoxib and  cyclosporine, monitor patients for signs of  worsening renal function.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" colspan="2" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold"> Â NSAIDs a</content>
                              <content styleCode="bold">nd  Salicylates</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="italics">Clinical  Impact:</content>
                              <br/>
                           </td>
                           <td align="justify" valign="top" styleCode="     Rrule     ">Â Concomitant use of Celecoxib  with other NSAIDs or  salicylates (e.g., diflunisal, salsalate) increases the risk of GI  toxicity, with little or no increase in efficacy [<content styleCode="italics">see <content styleCode="italics">
                                    <linkHtml href="#LINK_5069f2c7-1a91-4542-a9be-3aa4f8dbb0bc">Warnings and Precautions (5.2)</linkHtml>
                                 </content>
                              </content>]<content styleCode="italics">.</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="italics">Intervention:</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode="     Rrule     ">Â The concomitant use of Celecoxib  with other NSAIDs or  salicylates is not recommended.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" colspan="2" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold">Â Pemetrexed</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="italics">Clinical  Impact:</content>
                              <br/>
                           </td>
                           <td align="justify" valign="top" styleCode="     Rrule     ">Â Concomitant use of celecoxib and pemetrexed may increase the risk of pemetrexed-associated  myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information).<br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="italics">Intervention:</content>
                              <br/>
                           </td>
                           <td align="justify" valign="top" styleCode="     Rrule     ">Â During concomitant use of celecoxib and pemetrexed, in patients  with renal impairment  whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity.<br/>NSAIDs  with short elimination half-lives (e.g.,  diclofenac, indomethacin) should be avoided for a period of  two days before, the day of, and  two days  following administration of pemetrexed.<br/>In the absence of data regarding potential interaction  between pemetrexed and NSAIDs  with longer half-lives (e.g., meloxicam, nabumetone), patients taking these  NSAIDs should interrupt dosing for at least five  days before, the day of, and  two days  following pemetrexed administration.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" colspan="2" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold">Â CYP2C9 Inhibitors or inducers</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="italics">Clinical  Impact:</content>
                              <br/>
                           </td>
                           <td align="justify" valign="top" styleCode="     Rrule     ">Â Celecoxib metabolism is predominantly mediated via  cytochrome P450 (CYP) 2C9 in the liver. CoÂ­-administration of celecoxib  with drugs that are known to inhibit  CYP2C9 (e.g. fluconazole) may enhance the exposure and toxicity of celecoxib  whereas co-administration  with CYP2C9 inducers (e.g. rifampin) may lead to compromised efficacy of celecoxib.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="italics">Intervention</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode="     Rrule     ">Â Evaluate each patient's medical history  when consideration is  given to prescribing celecoxib. A dosage adjustment may be  warranted when celecoxib is administered  with CYP2C9 inhibitors or inducers. [<content styleCode="italics">see <content styleCode="italics">
                                    <linkHtml href="#LINK_1282d1e7-d3fe-4731-98c7-457eed99b078">Clinical  Pharmacology (12.3)</linkHtml>
                                 </content>
                              </content>].<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" colspan="2" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold"> Â CYP2D6</content>
                              <content styleCode="bold"> substrates</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="italics">Clinical  Impact:</content>
                              <br/>
                           </td>
                           <td align="justify" valign="top" styleCode="     Rrule     ">Â <content styleCode="italics">In vitro </content>studies  indicate that celecoxib, although not a substrate, is an inhibitor of CYP2D6. Therefore, there is a potential for an <content styleCode="italics">in vivo </content>drug interaction  with drugs that are metabolized by  CYP2D6 (e.g. atomoxetine), and celecoxib may enhance the exposure and toxicity of these drugs.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="italics">Intervention</content>
                              <br/>
                           </td>
                           <td align="justify" valign="top" styleCode="     Rrule     ">Â Evaluate each patient's medical history  when consideration is  given to prescribing celecoxib. A dosage adjustment may be  warranted when celecoxib is administered  with CYP2D6 substrates. [<content styleCode="italics">see <content styleCode="italics">
                                    <linkHtml href="#LINK_1282d1e7-d3fe-4731-98c7-457eed99b078">Clinical  Pharmacology (12.3)</linkHtml>
                                 </content>
                              </content>].<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" colspan="2" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold"> Â Corticosteroids</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="italics">Clinical  Impact:</content>
                              <br/>
                           </td>
                           <td align="justify" valign="top" styleCode="     Rrule     ">Â Concomitant use of corticosteroids  with celecoxib may increase the risk of GI ulceration or bleeding.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="italics">Intervention</content>
                              <br/>
                           </td>
                           <td align="justify" valign="top" styleCode="     Rrule     ">Â Monitor patients  with concomitant use of celecoxib  with corticosteroids for signs of bleeding [see <content styleCode="italics">
                                 <linkHtml href="#LINK_5069f2c7-1a91-4542-a9be-3aa4f8dbb0bc">Warnings and Precautions (5.2)</linkHtml>
                              </content>].<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20160517"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>
                              <content styleCode="underline">Drugs that Interfere  with Hemostasis (e.g. warfarin, aspirin,Â </content>
                              <content styleCode="underline">SSRIs/SNRIs)</content>: Monitor patients for bleeding  who are concomitantly taking celecoxib  with drugs that interfere  with hemostasis. Concomitant use of celecoxib and analgesic doses of aspirin is not generally  recommendedÂ <linkHtml href="#LINK_93869e4e-072e-4529-aef5-761fb3a6d1b1">(7)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="underline">ACE Inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-</content>
                              <content styleCode="underline">Blockers</content>: Concomitant use  with celecoxib may diminish the  antihypertensive effect of these drugs. Monitor blood pressure <linkHtml href="#LINK_93869e4e-072e-4529-aef5-761fb3a6d1b1">(7)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="underline">ACE Inhibitors and ARBs</content>: Concomitant use  with celecoxib in  elderly, volume depleted, or those  with renal impairment may result in deterioration of renal function. In such high risk  patients, monitor for signs of  worsening renal function <linkHtml href="#LINK_93869e4e-072e-4529-aef5-761fb3a6d1b1">(7)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="underline">Diuretics</content>: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including  antihypertensive effects <linkHtml href="#LINK_93869e4e-072e-4529-aef5-761fb3a6d1b1">(7)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="underline">Digoxin</content>: Concomitant use  with celecoxib can  increase serum concentration and prolong half-life of digoxin. Monitor serum digoxin levels <linkHtml href="#LINK_93869e4e-072e-4529-aef5-761fb3a6d1b1">(7)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_440c1c3a-24b8-4819-aee7-8243b20d27e1">
               <id root="440c1c3a-24b8-4819-aee7-8243b20d27e1"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8. USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20160517"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>
                              <content styleCode="underline"> Pregnancy:</content> Use of NSAIDs during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. Avoid use of NSAIDs in pregnant  women starting at 30  weeks of gestation <linkHtml href="#LINK_4785b1f6-62b6-4f3b-86f3-1c6d5e6adb2d">(5.10</linkHtml>, <linkHtml href="#LINK_f3aec266-21a6-4ac8-936c-cb2499eb89de">8.1)</linkHtml>
                           </item>
                           <item>
                              <content styleCode="underline"> Infertility:</content> NSAIDs  are associated  with reversible infertility. Consider  withdrawal of celecoxib in  women who have difficulties conceiving <linkHtml href="#LINK_eccf9714-b473-4b91-8ea0-cbe424df157a">(8.3)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_f3aec266-21a6-4ac8-936c-cb2499eb89de">
                     <id root="f3aec266-21a6-4ac8-936c-cb2499eb89de"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Pregnancy Category C. Pregnancy category D from 30 weeks of gestation onward. <br/>
                              <content styleCode="italics">
                                 <br/>Risk Summary <br/>
                              </content>
                           </content>
                           <br/>Use of NSAIDs, including celecoxib, during the third trimester of pregnancy increases the risk of premature closure of the fetal ductus arteriosus. Avoid use of NSAIDs, including celecoxib, in pregnant women starting at 30 weeks of gestation. <br/>
                           <br/>There are no adequate and well-controlled studies of celecoxib in pregnant women. Data from observational studies regarding potential  embryofetal risks of NSAID use in  women in the first or second trimesters of pregnancy are inconclusive. In the general U.S. population, all clinically recognized pregnancies, regardless of drug exposure, have a background rate of 2 to 4% for major malformations, and 15 to 20% for pregnancy loss. In animal reproduction studies,  embryo-fetal deaths and an increase in diaphragmatic hernias  were observed in rats administered celecoxib daily during the period of organogenesis at oral doses approximately 6 times the maximum  recommended human dose of 200 mg  twice daily. In addition, structural abnormalities (e.g., septal defects, ribs fused, sternebrae fused and sternebrae misshapen)  were observed in rabbits given daily oral doses of  celecoxib during the period of organogenesis at approximately 2 times the MRHD [see Data]. Based on animal data, prostaglandins have been  shown to have an important role in endometrial vascular  permeability, blastocyst implantation, and decidualization.  In animal studies, administration of prostaglandin synthesis inhibitors such as celecoxib, resulted in increased  pre- and post-implantation loss.<br/>
                           <content styleCode="bold">
                              <br/>Clinical Considerations</content>
                        </paragraph>
                        <content styleCode="bold">
                           <br/>
                        </content>
                        <paragraph>
                           <content styleCode="italics">
                              <br/>Labor or Delivery<br/>
                           </content>
                           <br/>There are no studies on the effects of celecoxib during labor or delivery. In animal studies, NSAIDs, including celecoxib, inhibit prostaglandin  synthesis, cause  delayed parturition, and increase the incidence of stillbirth.<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Data<br/>
                              </content>
                           </content>
                           <content styleCode="italics">
                              <br/>Human Data<br/>
                           </content>
                           <br/>The available data do not establish the presence or absence of developmental toxicity related to the use of celecoxib.<br/>
                           <content styleCode="italics">
                              <br/>Animal data</content>
                        </paragraph>
                        <content styleCode="italics">
                           <br/>
                        </content>
                        <br/>
                        <paragraph>Celecoxib at oral doses â¥150 mg/kg/day (approximately 2 times the human exposure at 200 mg  twice daily as measured by  AUC<sub>0-24</sub>), caused an increased incidence of ventricular septal defects, a rare event, and fetal alterations, such as ribs fused, sternebrae fused and sternebrae misshapen  when rabbits  were treated throughout organogenesis. A dose-dependent increase in diaphragmatic hernias  was observed  when rats were given celecoxib at oral doses â¥30 mg/kg/day (approximately 6 times human exposure based on the  AUC<sub>0-24</sub> at 200 mg  twice daily for RA) throughout organogenesis. In rats, exposure to celecoxib during early embryonic development resulted in pre-implantation and post-implantation losses at oral doses â¥50 mg/kg/day (approximately 6 times human exposure based on the  AUC<sub>0-24</sub> at 200 mg  twice daily for RA).<br/>
                           <br/>Celecoxib produced no evidence of  delayed labor or parturition at oral doses up to 100 mg/kg in rats (approximately 7-fold human exposure as measured by the AUC<sub> 0-24</sub> at 200 mg  twice daily). The effects of celecoxib on labor and delivery in pregnant women are  unknown.</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_0e2800b5-b6ea-4cbb-8235-4775edff5a16">
                     <id root="0e2800b5-b6ea-4cbb-8235-4775edff5a16"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Risk Summary<br/>
                              </content>
                           </content>
                           <br/>Limited data from 3 published reports that included a total of 12 breastfeeding  women showed low levels of celecoxib in breast  milk. The calculated average daily infant dose  was 10 to 40 mcg/kg/day, less than 1% of the  weight-based therapeutic dose for a two-year old-child. A report of  two breastfed infants 17 and 22 months of age did not show any adverse events. Caution should be exercised  when celecoxib is administered to a nursing  woman. The developmental and health benefits of breastfeeding should be considered along  with the motherâs  clinical need for celecoxib and any potential adverse effects on the breastfed infant from the celecoxib or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_eccf9714-b473-4b91-8ea0-cbe424df157a">
                     <id root="eccf9714-b473-4b91-8ea0-cbe424df157a"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics"> Infertility<br/>
                              </content>
                           </content>
                           <content styleCode="italics">
                              <br/>Females<br/>
                           </content>
                           <br/>Based on the mechanism of  action, the use of prostaglandin-mediated NSAIDs, including celecoxib, may delay or prevent rupture of ovarian  follicles, which has been associated  with reversible infertility in some  women. Published animal studies have  shown that administration of prostaglandin synthesis inhibitors has the potential to disrupt prostaglandin mediated follicular rupture required for ovulation. Small studies in  women treated with NSAIDs have also  shown a reversible delay in ovulation. Consider  withdrawal of NSAIDs, including celecoxib, in  women who have difficulties  conceiving or  who are undergoing  investigation of  infertility.</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_1cf60f83-1652-4f6a-a7c2-e0f788ab7233">
                     <id root="1cf60f83-1652-4f6a-a7c2-e0f788ab7233"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Celecoxib is approved for relief of the signs and symptoms of Juvenile Rheumatoid Arthritis in patients 2  years and older. Safety and efficacy have not been studied beyond six months in children. The long-term cardiovascular toxicity in children exposed to celecoxib has not been evaluated and it is  unknown if long-term risks may be similar to that seen in adults exposed to celecoxib or other COX-2 selective and nonÂ­selective  NSAIDs [<content styleCode="italics">(see <linkHtml href="#LINK_b39d30bb-5fbd-4132-8978-4d148679801b">Boxed Warning</linkHtml>, <linkHtml href="#LINK_dd021e2d-c6f0-4cd4-8414-527f3c2f9b7f">Warnings and Precautions (5.12)</linkHtml>, and <linkHtml href="#LINK_5abaaafe-b0a9-4160-832f-e41939fb2282">Clinical Studies (14.3)</linkHtml>
                           </content>].<br/>
                           <br/>The use of celecoxib in patients 2  years to 17 years of age  with pauciarticular,  polyarticular course JRA or in patients with  systemic onset JRA  was studied in a  12-week, double-blind, active  controlled, pharmacokinetic, safety and efficacy study,  with a 12-week  open-label extension. Celecoxib has not been studied in patients under the age of 2 years, in patients  with body weight less than 10 kg (22 lbs), and in patients  with active  systemic features. Patients  with systemic onset JRA  (without active  systemic features) appear to be at risk for the development of abnormal coagulation laboratory tests. In some patients  with systemic onset JRA, both celecoxib and naproxen  were associated with mild prolongation of activated partial thromboplastin time (APTT) but not prothrombin time (PT). When NSAIDs including celecoxib are used in patients  with systemic onset JRA, monitor patients for signs and  symptoms of abnormal clotting or bleeding, due to the risk of disseminated intravascular coagulation. Patients  with systemic onset JRA should be monitored for the development of abnormal coagulation tests [see <content styleCode="italics">
                              <linkHtml href="#LINK_c8516fe7-a59f-41e0-a8fa-0858a50a363e">Dosage and Administration (2.4)</linkHtml>, <linkHtml href="#LINK_dd021e2d-c6f0-4cd4-8414-527f3c2f9b7f">Warnings and Precautions (5.12)</linkHtml>, <linkHtml href="#LINK_ef9fb1b1-2af0-467d-83a9-5106ce454cfc">Adverse Reactions (6.3)</linkHtml>, <linkHtml href="#LINK_014fe024-e934-4be2-b4f3-eb7185f3bf77">Animal Toxicology (13.2)</linkHtml>, <linkHtml href="#LINK_5abaaafe-b0a9-4160-832f-e41939fb2282">Clinical  Studies (14.3)</linkHtml>
                           </content>]<content styleCode="italics">.<br/>
                           </content>
                           <br/>Alternative therapies for treatment of JRA should be considered in pediatric patients identified to be CYP2C9 poor metabolizers [see <linkHtml href="#LINK_b780e991-b07c-4c0e-bcfa-c2804559693a">Poor Metabolizers of CYP2C9 substrates (8.8)</linkHtml>].</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_3919496d-ba58-4d3b-a860-56e50d44d91c">
                     <id root="3919496d-ba58-4d3b-a860-56e50d44d91c"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Elderly patients, compared to younger patients, are at greater risk for NSAID-associated serious cardiovascular, gastrointestinal, and/or renal adverse reactions. If the anticipated benefit for the elderly patient outweighs these potential risks,  start dosing at the low end of the dosing range, and monitor patients for adverse effects [<content styleCode="italics">see </content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_d3863c12-5bb3-4999-8cbe-53ff3302917d">Warnings and Precautions (5.1</linkHtml>
                           </content>
                           <content styleCode="italics">, </content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_5069f2c7-1a91-4542-a9be-3aa4f8dbb0bc">5.2</linkHtml>
                           </content>
                           <content styleCode="italics">, </content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_123c45b9-a78a-40ef-ae49-d72c8d0bd6ba">5.3</linkHtml>
                           </content>
                           <content styleCode="italics">, </content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_2ce69f4f-9899-4506-91c2-9d2771f1355f">5.6</linkHtml>
                           </content>
                           <content styleCode="italics">, </content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_5830b273-2160-48ff-8fe6-0d9824863522">5.13)</linkHtml>
                           </content>].<br/>
                           <br/>Of the total number of patients who received celecoxib in pre-approval clinical trials, more than 3,300 were 65 to 74 years of age, while approximately 1,300 additional patients were 75 years and over. No substantial differences in effectiveness were observed between these subjects and younger subjects. In clinical studies comparing renal function as measured by the GFR, BUN and creatinine, and platelet function as measured by bleeding time and platelet aggregation, the results were not different between elderly and young volunteers.<br/>
                           <br/>However, as with other NSAIDs, including those that selectively inhibit COX-2, there have been more spontaneous post-marketing reports of fatal GI events and acute renal failure in the elderly than in younger patients [<content styleCode="italics">seeÂ </content>
                           <content styleCode="italics">
                              <content styleCode="italics">
                                 <linkHtml href="#LINK_7a44f63e-a433-4488-8e48-4e737b9afdf8">Warnings and Precautions (5.4</linkHtml>
                              </content>, <content styleCode="italics">
                                 <linkHtml href="#LINK_2ce69f4f-9899-4506-91c2-9d2771f1355f">5.6)</linkHtml>
                              </content>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_b8f55895-9834-4cd9-9451-c6e622fef01a">
                     <id root="b8f55895-9834-4cd9-9451-c6e622fef01a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Hepatic Impairment</title>
                     <text>
                        <paragraph>The daily recommended dose of celecoxib capsules in patients  with moderate hepatic impairment (Child-Pugh Class B) should be reduced by 50%. The use of celecoxib in patients  with severe hepatic impairment is not recommended [<content styleCode="italics">seeÂ <linkHtml href="#LINK_70f2416b-8784-4030-9e86-aae37fcc1771">Dosage and Administration (2.6)</linkHtml> and <linkHtml href="#LINK_1282d1e7-d3fe-4731-98c7-457eed99b078">Clinical  Pharmacology (12.3)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_59e807ff-6361-451d-a953-d69b7abdba58">
                     <id root="59e807ff-6361-451d-a953-d69b7abdba58"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.7 Renal Impairment</title>
                     <text>
                        <paragraph>Celecoxib is not recommended in patients  with severe renal insufficiency [<content styleCode="italics">seeÂ </content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_2ce69f4f-9899-4506-91c2-9d2771f1355f">Warnings and Precautions (5.6)</linkHtml>
                           </content>
                           <content styleCode="italics"> and </content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_1282d1e7-d3fe-4731-98c7-457eed99b078">Clinical Pharmacology  (12.3)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_b780e991-b07c-4c0e-bcfa-c2804559693a">
                     <id root="b780e991-b07c-4c0e-bcfa-c2804559693a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.8 Poor Metabolizers of CYP2C9 Substrates</title>
                     <text>
                        <paragraph>In patients  who are  known or suspected to be poor  CYP2C9 metabolizers (i.e.,  CYP2C9*3/*3), based on genotype or previous  history/experience with other  CYP2C9 substrates (such as  warfarin, phenytoin) administer celecoxib starting  with half the  lowest recommended dose. Alternative management should be considered in JRA patients identified to be  CYP2C9 poor metabolizers. [<content styleCode="italics">seeÂ <linkHtml href="#LINK_70f2416b-8784-4030-9e86-aae37fcc1771">Dosage and Administration (2.6)</linkHtml> and <linkHtml href="#LINK_5f779a72-3d7d-4f1b-80c5-323ec77a403f">Clinical  Pharmacology (12.5)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_e0c47c05-8ee2-4088-bcb0-da3b329626f2">
               <id root="e0c47c05-8ee2-4088-bcb0-da3b329626f2"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10. OVERDOSAGE</title>
               <text>
                  <paragraph> Symptoms following acute NSAID overdosages have been typically limited to lethargy,  drowsiness, nausea, vomiting, and epigastric pain,  which have been generally  reversible with supportive care. Gastrointestinal bleeding has occurred. Hypertension, acute renal failure,  respiratory depression, and coma have occured, but  were rare [<content styleCode="italics">see  <linkHtml href="#LINK_d3863c12-5bb3-4999-8cbe-53ff3302917d">Warnings and Precautions (5.1</linkHtml>,Â <linkHtml href="#LINK_5069f2c7-1a91-4542-a9be-3aa4f8dbb0bc">5.2</linkHtml>, <linkHtml href="#LINK_7a44f63e-a433-4488-8e48-4e737b9afdf8">5.4</linkHtml>, <linkHtml href="#LINK_2ce69f4f-9899-4506-91c2-9d2771f1355f">5.6)</linkHtml>
                     </content>].<br/>
                     <br/>No overdoses of celecoxib were reported during clinical trials. Doses up to 2400 mg/day for up to 10 days in 12 patients did not result in serious toxicity. No information is available regarding the removal of celecoxib by hemodialysis, but based on its high degree of plasma protein binding (&gt;97%) dialysis is unlikely to be useful in overdose.<br/>
                     <br/>Manage patients with symptomatic and supportive care following an NSAID overdosage. There are no specific antidotes. Consider emesis and/or activated charcoal (60 to 100 grams in adults, 1 to 2 grams per kg of body weight in pediatric patients) and/or osmotic cathartic in symptomatic patients seen within four hours of ingestion or in patients with a large overdosage (5 to 10 times the recommended dosage). Forced diuresis, alkalinization of urine, hemodialysis, or hemoperfusion may not be useful due to high protein binding.<br/>
                     <br/>For additional information about overdosage treatment contact a poison control center (1-800-222-1222).</paragraph>
               </text>
               <effectiveTime value="20160517"/>
            </section>
         </component>
         <component>
            <section ID="LINK_2deedeff-62bf-46bc-88b7-abd78aceb64c">
               <id root="2deedeff-62bf-46bc-88b7-abd78aceb64c"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11. DESCRIPTION</title>
               <text>
                  <paragraph>Celecoxib capsule is a nonsteroidal anti-inflammatory drug, available as capsules containing 50 mg, 100 mg, 200 mg and 400 mg celecoxib USP for oral administration. The chemical name is 4-[5-(4-methylphenyl)- 3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide and is a  diaryl-substituted pyrazole. The molecular  weight is 381.38. Its molecular formula is  C<sub>17</sub>H<sub>14</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub>S, and it has the  following chemical structure:<br/>
                     <br/>
                     <renderMultiMedia referencedObject="MM1"/>
                     <br/>
                     <br/>Celecoxib is a white or almost  white  crystalline powder  with a pKa of 11.1 (sulfonamide  moiety). Celecoxib is soluble to freely soluble in ethanol, soluble in methylene chloride and practically insoluble in water.<br/>
                     <br/>The inactive ingredients in celecoxib capsules include: crospovidone, hydroxypropyl cellulose, lactose monohydrate, povidone, sodium lauryl sulfate, sodium stearyl fumarate. The  empty hard gelatin capsule shells contain gelatin and titanium dioxide. The capsules are imprinted with edible ink containing propylene glycol and shellac. In addition, 50 mg capsules are imprinted with FD&amp;C Red #40 aluminum lake and sodium hydroxide. 100 mg capsules are imprinted with FD &amp; C Blue # 2 aluminum lake and strong ammonia solution. 200 mg capsules are imprinted with strong ammonia solution and yellow iron oxide. 400 mg capsules are imprinted with FD &amp; C Blue # 2 aluminum lake, strong ammonia solution and yellow iron oxide.</paragraph>
               </text>
               <effectiveTime value="20160517"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="celecoxib-capsules---aurobindo-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_3f72ca04-03e4-48d6-80bb-93833691a028">
               <id root="3f72ca04-03e4-48d6-80bb-93833691a028"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12. CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20160517"/>
               <component>
                  <section ID="LINK_2500af75-caee-49bf-b718-af9acb692b64">
                     <id root="2500af75-caee-49bf-b718-af9acb692b64"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph> Celecoxib has analgesic,  anti-inflammatory, and  antipyretic properties.<br/>
                           <br/>The mechanism of action of celecoxib is believed to be due to inhibition of prostaglandin synthesis, primarily via  inhibition of  cyclooxygenase-2 (COX-2).<br/>
                           <br/>Celecoxib is a potent inhibitor of prostaglandin synthesis <content styleCode="italics">in vitro</content>. Celecoxib concentrations reached during therapy have produced <content styleCode="italics">in vivo</content> effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Since celecoxib is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues.</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_16202f21-e009-4128-b5c5-60dccddbe86e">
                     <id root="16202f21-e009-4128-b5c5-60dccddbe86e"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Platelets<br/>
                              </content>
                           </content>
                           <br/>In  clinical trials using normal volunteers, celecoxib at single doses up to 800 mg and multiple doses of 600 mg  twice daily for up to 7 days duration (higher than recommended therapeutic doses) had no effect on reduction of platelet aggregation or increase in bleeding time. Because of its  lack of platelet effects, celecoxib is not a substitute for aspirin for cardiovascular  prophylaxis. It is not  known if there are any effects of celecoxib on platelets that may contribute to the increased risk of serious cardiovascular thrombotic adverse events  associated with the use of celecoxib.<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Fluid</content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics"> Retention<br/>
                              </content>
                           </content>
                           <br/>Inhibition of PGE2  synthesis may lead to sodium and water retention through increased reabsorption in the renal medullary thick ascending loop of Henle and perhaps other segments of the distal nephron. In the collecting ducts, PGE2 appears to inhibit  water reabsorption by counteracting the action of antidiuretic hormone.</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_1282d1e7-d3fe-4731-98c7-457eed99b078">
                     <id root="1282d1e7-d3fe-4731-98c7-457eed99b078"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Celecoxib exhibits dose-proportional  increase in exposure after oral administration up to 200 mg twice daily and less than proportional increase at higher doses. It has extensive distribution and high protein binding. It is primarily metabolized by  CYP2C9 with a half-life of approximately 11 hours.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics"> Absorption</content>
                           </content>
                        </paragraph>
                        <br/>
                        <paragraph>Peak plasma levels of celecoxib occur approximately 3 hrs after an oral dose. Under fasting conditions, both peak plasma levels  (C<sub>max</sub>) and area under the  curve (AUC)  are roughly  dose-proportional up to 200 mg  twice daily; at higher doses there are less than proportional increases in C<sub> max</sub> and AUC <content styleCode="italics">[see Food Effects]</content>. Absolute bioavailability studies have not been conducted. With multiple dosing,  steady-state conditions are reached on or before Day 5. The pharmacokinetic parameters of celecoxib in a group of healthy subjects are  shown in Table 4.</paragraph>
                        <table>
                           <caption>Table 4 Summary of Single Dose (200 mg) Disposition Kinetics of Celecoxib in Healthy Subjects<sup>1</sup>
                           </caption>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <tfoot>
                              <tr>
                                 <td>Â <sup>1</sup> Subjects under fasting conditions (n=36,  19 to  52 yrs.)<br/>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" valign="top" colspan="5" styleCode="    Lrule          Rrule     ">Â Mean  (%CV) PK Parameter Values<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold">C</content>
                                    <sub>m</sub>
                                    <sub>ax,</sub>
                                    <content styleCode="bold"> ng/mL</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold"> T<sub>max</sub>,</content>
                                    <content styleCode="bold"> hr</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold"> Effective</content>
                                    <content styleCode="bold"> t<sub>1/2</sub>,</content>
                                    <content styleCode="bold"> hr</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold"> Vss/F,</content>
                                    <content styleCode="bold">L</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â <content styleCode="bold"> CL/F,</content>
                                    <content styleCode="bold"> L/hr</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" valign="top" styleCode="    Lrule          Rrule     ">Â  705 (38)<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â  2.8 (37)<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â  11.2 (31)<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â  429 (34)<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â  27.7 (28)<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Food Effects<br/>
                              </content>
                           </content>
                           <br/>When celecoxib capsules  were taken  with a high fat meal, peak plasma levels  were delayed for about 1 to 2 hours  with an increase in total absorption (AUC) of 10% to 20%. Under fasting conditions, at doses above 200 mg, there is less than a proportional increase in C<sub> max</sub> and AUC,  which is thought to be due to the low solubility of the drug in aqueous media.<br/>
                           <br/>Coadministration of celecoxib  with an aluminum- and magnesium-containing antacids resulted in a reduction in plasma celecoxib concentrations with a decrease of 37% in C<sub> max</sub>and 10% in AUC. Celecoxib, at doses up to 200 mg twice  daily, can be administered  without regard to timing of meals. Higher doses (400 mg  twice daily) should be administered  with food to improve absorption.<br/>
                           <br/>In healthy adult volunteers, the overall  systemic exposure (AUC) of celecoxib  was equivalent  when celecoxib  was administered as intact capsule or capsule contents sprinkled on applesauce. There were no significant  alterations in C<sub> max, </sub>T<sub> max </sub>or t<sub>1/2 </sub>after administration of capsule contents on applesauce [<content styleCode="italics">see <linkHtml href="#LINK_3de1f64d-82a0-4d0e-a25f-a6cf26f27190">Dosage and  Administration (2)</linkHtml>
                           </content>].<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Distribution<br/>
                              </content>
                           </content>
                           <br/>In healthy subjects, celecoxib is highly protein bound (~97%)  within the  clinical dose range. <content styleCode="italics">In vitro </content>studies indicate that celecoxib binds primarily to albumin and, to a lesser extent,  Î±<sub>1</sub>-acid glycoprotein. The apparent volume of distribution at steady state (Vss/F) is approximately 400 L, suggesting extensive distribution into the tissues. Celecoxib is not preferentially bound to red blood cells.<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Elimination<br/>
                              </content>
                           </content>
                           <content styleCode="italics">
                              <br/>Metabolism<br/>
                           </content>
                           <br/>Celecoxib metabolism is primarily mediated via CYP2C9. Three metabolites, a primary alcohol, the corresponding carboxylic acid and its glucuronide conjugate, have been identified in human plasma. These metabolites are inactive as COX-1 or COX-2 inhibitors.<br/>
                           <content styleCode="italics">
                              <br/>Excretion<br/>
                           </content>
                           <br/>Celecoxib is eliminated predominantly by hepatic metabolism with little (&lt;3%) unchanged drug recovered in the urine and feces. Following a single oral dose of radiolabeled drug, approximately 57% of the dose was excreted in the feces and 27% was excreted into the urine. The primary metabolite in both urine and feces was the carboxylic acid metabolite (73% of dose) with low amounts of the glucuronide also appearing in the urine. It appears that the low solubility of the drug prolongs the absorption process making terminal half-life (t<sub>1/2</sub>) determinations more variable. The effective half-life is approximately 11 hours under fasted conditions. The apparent plasma clearance (CL/F) is about 500 mL/min.<br/>
                           <content styleCode="bold">
                              <br/>Specific P</content>
                           <content styleCode="bold">opulations<br/>
                           </content>
                           <content styleCode="italics">
                              <br/>Geriatric<br/>
                           </content>
                           <br/>At steady state, elderly subjects (over 65 years old) had a 40% higher C<sub>max</sub>and a 50% higher AUC compared to the young subjects. In elderly females, celecoxib C<sub>max</sub>Â  and AUC are higher than those for elderly males, but these increases are predominantly due to lower body weight in elderly females. Dose adjustment in the elderly is not generally necessary. However, for patients of less than 50 kg in body weight, initiate therapy at the lowest recommended dose [<content styleCode="italics">seeÂ <linkHtml href="#LINK_34b62d78-e046-45be-a205-884e22cd4152">Dosage and Administration (2.7)</linkHtml> and <linkHtml href="#LINK_3919496d-ba58-4d3b-a860-56e50d44d91c">Use in Specific Populations (8.5)</linkHtml>
                           </content>].<br/>
                           <content styleCode="italics">
                              <br/>Pediatric<br/>
                           </content>
                           <br/>The steady state pharmacokinetics of celecoxib administered as an investigational oral suspension was evaluated in 152 JRA patients 2 years to 17 years of age weighing â¥10 kg with pauciarticular or polyarticular course JRA and in patients with systemic onset JRA. Population pharmacokinetic analysis indicated that the oral clearance (unadjusted for body weight) of celecoxib increases less than proportionally to increasing weight, with 10 kg and 25 kg patients predicted to have 40% and 24% lower clearance, respectively, compared with a 70 kg adult RA patient.<br/>
                           <br/>Twice-daily administration of 50 mg capsules to JRA patients weighing â¥12 to â¤25 kg and 100 mg capsules to JRA patients weighing &gt;25 kg should achieve plasma concentrations similar to those observed in a clinical trial that demonstrated the non-inferiority of celecoxib to naproxen 7.5 mg/kg twice daily (<content styleCode="italics">see <linkHtml href="#LINK_c8516fe7-a59f-41e0-a8fa-0858a50a363e">Dosage and Administration (2.4)</linkHtml>. </content>Celecoxib has not been studied in JRA patients under the age of 2 years, in patients with body weight less than 10 kg (22 lbs), or beyond 24 weeks.<br/>
                           <content styleCode="italics">
                              <br/>Race<br/>
                           </content>
                           <br/>Meta-analysis of pharmacokinetic studies has suggested an approximately 40% higher AUC of celecoxib in Blacks compared to Caucasians. The cause and clinical significance of this finding is unknown.<br/>
                           <content styleCode="italics">
                              <br/>Hepatic Impairment<br/>
                           </content>
                           <br/>A pharmacokinetic study in subjects with mild (Child-Pugh Class A) and moderate (Child-Pugh Class B) hepatic impairment has shown that steady-state celecoxib AUC is increased about 40% and 180%, respectively, above that seen in healthy control subjects. Therefore, the daily recommended dose of celecoxib capsules should be reduced by approximately 50% in patients with moderate (Child-Pugh Class B) hepatic impairment. Patients with severe hepatic impairment (Child-Pugh Class C) have not been studied. The use of celecoxib in patients with severe hepatic impairment is not recommended [<content styleCode="italics">seeÂ <linkHtml href="#LINK_70f2416b-8784-4030-9e86-aae37fcc1771">Dosage and Administration (2.6)</linkHtml> and <linkHtml href="#LINK_b8f55895-9834-4cd9-9451-c6e622fef01a">Use in Specific Populations (8.6)</linkHtml>
                           </content>].<br/>
                           <content styleCode="italics">
                              <br/>Renal Impairment<br/>
                           </content>
                           <br/>In a cross-study comparison, celecoxib AUC was approximately 40% lower in patients with chronic renal insufficiency (GFR 35 to 60 mL/min) than that seen in subjects with normal renal function. No significant relationship was found between GFR and celecoxib clearance. Patients with severe renal insufficiency have not been studied. Similar to other NSAIDs, celecoxib is not recommended in patients with severe renal insufficiency [<content styleCode="italics">see <linkHtml href="#LINK_2ce69f4f-9899-4506-91c2-9d2771f1355f">Warnings and Precautions (5.6)</linkHtml>
                           </content>].<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Drug I</content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics">nteraction S</content>
                           </content>
                           <content styleCode="bold">
                              <content styleCode="italics">tudies<br/>
                              </content>
                           </content>
                           <content styleCode="italics">
                              <br/>In vitro studies </content>indicate that celecoxib is not an inhibitor of cytochrome P450 2C9, 2C19 or 3A4.<br/>
                           <content styleCode="italics">
                              <br/>In vivo studies have shown the following: <br/>
                           </content>
                           <content styleCode="italics">
                              <br/>Aspirin<br/>
                           </content>
                           <br/>When NSAIDs were administered with aspirin, the protein binding of NSAIDs were reduced, although the clearance of free NSAID was not altered. The clinical significance of this interaction is not known. See Table 3 for clinically significant drug interactions of NSAIDs with aspirin [<content styleCode="italics">see <linkHtml href="#LINK_93869e4e-072e-4529-aef5-761fb3a6d1b1">Drug Interactions (7)</linkHtml>
                           </content>]<content styleCode="italics">.<br/>
                           </content>
                           <content styleCode="italics">
                              <br/>Lithium<br/>
                           </content>
                           <br/>In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg twice daily with celecoxib 200 mg twice daily as compared to subjects receiving lithium alone [<content styleCode="italics">see <linkHtml href="#LINK_93869e4e-072e-4529-aef5-761fb3a6d1b1">Drug Interactions (7)</linkHtml>
                           </content>].<br/>
                           <content styleCode="italics">
                              <br/>Fluconazole<br/>
                           </content>
                           <br/>Concomitant administration of fluconazole at 200 mg once daily resulted in a two-fold increase in celecoxib plasma concentration. This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole [<content styleCode="italics">see <linkHtml href="#LINK_93869e4e-072e-4529-aef5-761fb3a6d1b1">Drug Interactions (7)</linkHtml>
                           </content>].<br/>
                           <content styleCode="italics">
                              <br/>Other D</content>
                           <content styleCode="italics">rugs<br/>
                           </content>
                           <br/>The effects of celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, [<content styleCode="italics">see <linkHtml href="#LINK_93869e4e-072e-4529-aef5-761fb3a6d1b1">Drug Interactions (7)</linkHtml>
                           </content>], phenytoin, and tolbutamide have been studied <content styleCode="italics">in vivo </content>and clinically important interactions have not been found.</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_5f779a72-3d7d-4f1b-80c5-323ec77a403f">
                     <id root="5f779a72-3d7d-4f1b-80c5-323ec77a403f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.5 Pharmacogenomics</title>
                     <text>
                        <paragraph> CYP2C9 activity is reduced in individuals  with genetic  polymorphisms that lead to reduced  enzyme activity, such as those  homozygous for the CYP2C9*2 and CYP2C9*3 polymorphisms. Limited data from 4 published reports that included a total of 8 subjects  with the  homozygous CYP2C9*3/*3 genotype showed celecoxib  systemic levels that  were 3- to 7-fold higher in these subjects compared to subjects  with CYP2C9*1/*1 or *I/*3 genotypes. The pharmacokinetics of celecoxib have not been evaluated in subjects  with other  CYP2C9 polymorphisms, such as *2, *5, *6, *9 and *11. It is estimated that the frequency of the homozygous *3/*3 genotype is 0.3% to 1% in various ethnic groups. [<content styleCode="italics">see <linkHtml href="#LINK_70f2416b-8784-4030-9e86-aae37fcc1771">Dosage and Administration (2.6)</linkHtml>, <linkHtml href="#LINK_b780e991-b07c-4c0e-bcfa-c2804559693a">Use in Specific Populations (8.8)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_c1cd11b5-8011-48b5-8c15-215298a381df">
               <id root="c1cd11b5-8011-48b5-8c15-215298a381df"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13. NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20160517"/>
               <component>
                  <section ID="LINK_872d99f1-4184-4d3f-91a2-ee40c3112e8a">
                     <id root="872d99f1-4184-4d3f-91a2-ee40c3112e8a"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Carcinogenesis</content>
                           </content>
                           <br/>
                           <br/>Celecoxib was not carcinogenic in Sprague-Dawley rats given oral doses up to 200 mg/kg for males and 10 mg/kg for females (approximately 2-to 4-times the human exposure as measured by the AUC<sub>0-24</sub> at 200 mg twice daily) or in mice given oral doses up to 25 mg/kg for males and 50 mg/kg for females (approximately equal to human exposure as measured by the AUC<sub>0-24</sub> at 200 mg twice daily) for two years.<br/>
                           <br/>
                           <content styleCode="bold">
                              <content styleCode="italics">Mutagenesis</content>
                           </content>
                           <br/>
                           <br/>Celecoxib was not mutagenic in an Ames test and a mutation assay in Chinese hamster ovary (CHO) cells, nor clastogenic in a chromosome aberration assay in CHO cells and an <content styleCode="italics">in vivo</content> micronucleus test in rat bone marrow.<br/>
                           <br/>
                           <content styleCode="bold">
                              <content styleCode="italics">Impairment of Fertility<br/>
                                 <br/>
                              </content>
                           </content>Celecoxib had no effect on male or female fertility or male reproductive function in rats at oral doses up to 600 mg/kg/day (approximately 11Â­times human exposure at 200 mg twice daily based on the AUC<sub>0-24</sub>). At â¥50 mg/kg/day (approximately 6-times human exposure based on the AUC<sub>0-24</sub> at 200 mg twice daily) there was increased preimplantation loss.</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_014fe024-e934-4be2-b4f3-eb7185f3bf77">
                     <id root="014fe024-e934-4be2-b4f3-eb7185f3bf77"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2 Animal Toxicology</title>
                     <text>
                        <paragraph>An increase in the incidence of background findings of spermatocele  with or  without secondary changes such as  epididymal hypospermia as  well as minimal to slight dilation  of the seminiferous tubules  was seen in the juvenile rat. These reproductive findings  while apparently treatment-related did not increase in incidence or severity  with dose and may indicate an exacerbation of a spontaneous condition.  Similar reproductive findings  were not observed in studies of juvenile or adult dogs or in adult rats treated  with celecoxib. The clinical  significance of this observation is  unknown.</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_5513f7bd-08f8-4570-918a-5effc6e9a402">
               <id root="5513f7bd-08f8-4570-918a-5effc6e9a402"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14. CLINICAL STUDIES</title>
               <effectiveTime value="20160517"/>
               <component>
                  <section ID="LINK_8031dd46-6144-4922-905d-d347808f267d">
                     <id root="8031dd46-6144-4922-905d-d347808f267d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Osteoarthritis</title>
                     <text>
                        <paragraph>Celecoxib has demonstrated significant reduction in joint pain compared to placebo. Celecoxib was evaluated for treatment of the signs and the symptoms of OA of the knee and hip in placebo- and active-controlled clinical trials of up to 12 weeks duration. In patients with OA, treatment with celecoxib 100 mg twice daily or 200 mg once daily resulted in improvement in WOMAC (Western Ontario and McMaster Universities) osteoarthritis index, a composite of pain, stiffness, and functional measures in OA. In three 12-week studies of pain accompanying OA flare, celecoxib doses of 100 mg twice daily and 200 mg twice daily provided significant reduction of pain within 24 to 48 hours of initiation of dosing. At doses of 100 mg twice daily or 200 mg twice daily the effectiveness of celecoxib was shown to be similar to that of naproxen 500 mg twice daily. Doses of 200 mg twice daily provided no additional benefit above that seen with 100 mg twice daily. A total daily dose of 200 mg has been shown to be equally effective whether administered as 100 mg twice daily or 200 mg once daily.</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_7110df1c-07ac-4450-b492-3db14795a38c">
                     <id root="7110df1c-07ac-4450-b492-3db14795a38c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Rheumatoid Arthritis</title>
                     <text>
                        <paragraph>Celecoxib has demonstrated significant reduction in joint tenderness/pain and joint swelling compared to placebo. Celecoxib was evaluated for treatment of the signs and symptoms of RA in placebo- and active-controlled clinical trials of up to 24 weeks in duration. Celecoxib was shown to be superior to placebo in these studies, using the ACR20 Responder Index, a composite of clinical, laboratory, and functional measures in RA. Celecoxib doses of 100 mg twice daily and 200 mg twice daily were similar in effectiveness and both were comparable to naproxen 500 mg twice daily.<br/>
                           <br/>Although celecoxib 100 mg twice daily and 200 mg twice daily provided similar overall effectiveness, some patients derived additional benefit from the 200 mg twice daily dose. Doses of 400 mg twice daily provided no additional benefit above that seen with 100 to 200 mg twice daily.</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_5abaaafe-b0a9-4160-832f-e41939fb2282">
                     <id root="5abaaafe-b0a9-4160-832f-e41939fb2282"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.3 Juvenile Rheumatoid Arthritis</title>
                     <text>
                        <paragraph>In a 12-week, randomized, double-blind active-controlled, parallel-group, multicenter, non-inferiority study, patients from 2 years to 17 years of age with pauciarticular, polyarticular course JRA or systemic onset JRA (with currently inactive systemic features), received one of the following treatments: celecoxib 3 mg/kg (to a maximum of 150 mg) twice daily; celecoxib 6 mg/kg (to a maximum of 300 mg) twice daily; or naproxen 7.5 mg/kg (to a maximum of 500 mg) twice daily. The response rates were based upon the JRA Definition of Improvement greater than or equal to 30% (JRA DOI 30) criterion, which is a composite of clinical, laboratory, and functional measures of JRA. The JRA DOI 30 response rates at week 12 were 69%, 80% and 67% in the celecoxib 3 mg/kg twice daily, celecoxib 6 mg/kg twice daily, and naproxen 7.5 mg/kg twice daily treatment groups, respectively.<br/>
                           <br/>The efficacy and safety of celecoxib for JRA have not been studied beyond six months. The long-term cardiovascular toxicity in children exposed to celecoxib has not been evaluated and it is unknown if the long-term risk may be similar to that seen in adults exposed to celecoxib or other COX-2 selective and non-selective NSAIDs [(<content styleCode="italics">see <linkHtml href="#LINK_b39d30bb-5fbd-4132-8978-4d148679801b">Boxed Warning</linkHtml>, <linkHtml href="#LINK_dd021e2d-c6f0-4cd4-8414-527f3c2f9b7f">Warnings and Precautions (5.12)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_330456de-1c3a-47dd-bdce-ff6fd7ba1d42">
                     <id root="330456de-1c3a-47dd-bdce-ff6fd7ba1d42"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.4 Ankylosing Spondylitis</title>
                     <text>
                        <paragraph>Celecoxib was evaluated in AS patients in two placebo- and active-controlled clinical trials of 6 and 12 weeks duration. Celecoxib at doses of 100 mg twice daily, 200 mg once daily and 400 mg once daily was shown to be statistically superior to placebo in these studies for all three co-primary efficacy measures assessing global pain intensity (Visual Analogue Scale), global disease activity (Visual Analogue Scale) and functional impairment (Bath Ankylosing Spondylitis Functional Index). In the 12-week study, there was no difference in the extent of improvement between the 200 mg and 400 mg celecoxib doses in a comparison of mean change from baseline, but there was a greater percentage of patients who responded to celecoxib 400 mg, 53%, than to celecoxib 200 mg, 44%, using the Assessment in Ankylosing Spondylitis response criteria (ASAS 20). The ASAS 20 defines a responder as improvement from baseline of at least 20% and an absolute improvement of at least 10 mm, on a 0 to 100 mm scale, in at least three of the four following domains: patient global pain, Bath Ankylosing Spondylitis Functional Index, and inflammation. The responder analysis also demonstrated no change in the responder rates beyond 6 weeks.</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_8c4c2711-ec6e-4d00-b8e7-30d61e78fe7d">
                     <id root="8c4c2711-ec6e-4d00-b8e7-30d61e78fe7d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.5 Analgesia, including Primary Dysmenorrhea</title>
                     <text>
                        <paragraph>In acute analgesic models of post-oral surgery pain, post-orthopedic surgical pain, and primary dysmenorrhea, celecoxib relieved pain that was rated by patients as moderate to severe. Single doses [<content styleCode="italics">see <linkHtml href="#LINK_70f2416b-8784-4030-9e86-aae37fcc1771">Dosage and Administration (2.6)</linkHtml>
                           </content>] of celecoxib provided pain relief within 60 minutes.</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c3b28510-93cc-4660-a903-8a090301704c">
                     <id root="c3b28510-93cc-4660-a903-8a090301704c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.6 Special Studies</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Adenomatous Polyp Prevention Studies</content>
                        </paragraph>
                        <paragraph>Cardiovascular safety was evaluated in two randomized, double-blind, placebo-controlled, three year studies involving patients with Sporadic Adenomatous Polyps treated with celecoxib: the APC trial (Adenoma Prevention with Celecoxib) and the PreSAP trial (Prevention of Spontaneous Adenomatous Polyps). In the APC trial, there was a dose-related increase in the composite endpoint (adjudicated) of cardiovascular death, myocardial infarction, or stroke with celecoxib compared to placebo over 3 years of treatment. The PreSAP trial did not demonstrate a statistically significant increased risk for the same composite endpoint (adjudicated):</paragraph>
                        <br/>
                        <list listType="unordered" styleCode="Disk">
                           <item>In the APC trial, the hazard ratios compared to placebo for a composite endpoint (adjudicated) of cardiovascular death, myocardial infarction, or stroke were 3.4 (95% CI 1.4Â to 8.5) with celecoxib 400 mg twice daily and 2.8 (95% CI 1.1 to 7.2) with celecoxib 200 mg twice daily. Cumulative rates for this composite endpoint over 3 years were 3% (20/671 subjects) and 2.5% (17/685 subjects), respectively, compared to 0.9% (6/679 subjects) with placebo treatment. The increases in both celecoxib dose groups versus placebo-treated patients were mainly due to an increased incidence of myocardial infarction.</item>
                           <item>In the PreSAP trial, the hazard ratio for this same composite endpoint (adjudicated) was 1.2 (95% CI 0.6 to 2.4) with celecoxib 400 mg once daily compared to placebo. Cumulative rates for this composite endpoint over 3 years were 2.3% (21/933 subjects) and 1.9% (12/628 subjects), respectively.</item>
                        </list>
                        <paragraph>Clinical trials of other COX-2 selective and non-selective NSAIDs of up to three-years duration have shown an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. As a result, all NSAIDs are considered potentially associated with this risk.<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Celecoxib Long-Term Arthritis Safety Study (CLASS)<br/>
                              </content>
                           </content>
                           <br/>This was a prospective, long-term, safety outcome study conducted post-marketing in approximately 5,800 OA patients and 2,200 RA patients. Patients received celecoxib 400 mg twice daily (4-fold and 2-fold the recommended OA and RA doses, respectively), ibuprofen 800 mg three times daily or diclofenac 75 mg twice daily (common therapeutic doses). Median exposures for celecoxib (n = 3,987) and diclofenac (n = 1,996) were 9 months while ibuprofen (n = 1,985) was 6 months. The primary endpoint of this outcome study was the incidence of complicated ulcers (gastrointestinal bleeding, perforation or obstruction). Patients were allowed to take concomitant low-dose (â¤ 325 mg/day) aspirin (ASA) for cardiovascular prophylaxis (ASA subgroups: celecoxib, n = 882; diclofenac, n = 445; ibuprofen, n = 412). Differences in the incidence of complicated ulcers between celecoxib and the combined group of ibuprofen and diclofenac were not statistically significant.<content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>
                              </content>
                           </content>
                           <br/>Patients on celecoxib and concomitant low-dose ASA (N=882) experienced 4-fold higher rates of complicated ulcers compared to those not on ASA (N=3105). The Kaplan-Meier rate for complicated ulcers at 9 months was 1.12% versus 0.32% for those on low-dose ASA and those not on ASA, respectively [<content styleCode="italics">see <linkHtml href="#LINK_7a44f63e-a433-4488-8e48-4e737b9afdf8">Warnings and Precautions (5.4)</linkHtml>
                           </content>].<br/>
                           <br/>The estimated cumulative rates at 9 months of complicated and symptomatic ulcers for patients treated with celecoxib 400 mg twice daily are described in Table 4. Table 4 also displays results for patients less than or greater than 65 years of age. The difference in rates between celecoxib alone and celecoxib with ASA groups may be due to the higher risk for GI events in ASA users.</paragraph>
                        <table>
                           <caption>Table 5: Complicated and Symptomatic Ulcer Rates in Patients Taking Celecoxib 400 mg Twice Daily (Kaplan-Meier Rates at 9 months [%]) Based on Risk Factors</caption>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold">Â All Patients </content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode="     Rrule     ">Â </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="    Lrule          Rrule     ">Â Â Celecoxib alone (n=3105)<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 0.78<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="    Lrule          Rrule     ">Â Â Celecoxib with ASA (n=882)<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 2.19<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold">
                                       <content styleCode="italics">Â Patients &lt;65 Years </content>
                                    </content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="    Lrule          Rrule     ">Â Â Celecoxib alone (n=2025)<br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 0.47<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="    Lrule          Rrule     ">Â Â Celecoxib with ASA (n=403) <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 1.26<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="    Lrule          Rrule     ">Â <content styleCode="bold">Â Patients â¥65 Years </content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="    Lrule          Rrule     ">Â Â Celecoxib alone (n=1080) <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 1.4<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="    Lrule          Rrule     ">Â Â Celecoxib with ASA (n=479) <br/>
                                 </td>
                                 <td align="center" valign="top" styleCode="     Rrule     ">Â 3.06<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In a small number of patients with a history of ulcer disease, the complicated and symptomatic ulcer rates in patients taking celecoxib alone or celecoxib with ASA were, respectively, 2.56% (n=243) and 6.85% (n=91) at 48 weeks. These results are to be expected in patients with a prior history of ulcer disease [<content styleCode="italics">seeÂ <linkHtml href="#LINK_7a44f63e-a433-4488-8e48-4e737b9afdf8">Warnings and Precautions (5.4)</linkHtml> andÂ  <linkHtml href="#LINK_e87c3e20-ab8a-42f0-b0e5-23bb74f2a37f">Adverse Reactions (6.1)</linkHtml>
                           </content>].<br/>
                           <br/>Cardiovascular safety outcomes were also evaluated in the CLASS trial. Kaplan-Meier cumulative rates for investigator-reported serious cardiovascular thromboembolic adverse events (including MI, pulmonary embolism, deep venous thrombosis, unstable angina, transient ischemic attacks, and ischemic cerebrovascular accidents) demonstrated no differences between the celecoxib, diclofenac, or ibuprofen treatment groups. The cumulative rates in all patients at nine months for celecoxib, diclofenac, and ibuprofen were 1.2%, 1.4%, and 1.1%, respectively. The cumulative rates in non-ASA users at nine months in each of the three treatment groups were less than 1%. The cumulative rates for myocardial infarction in non-ASA users at nine months in each of the three treatment groups were less than 0.2%. There was no placebo group in the CLASS trial, which limits the ability to determine whether the three drugs tested had no increased risk of CV events or if they all increased the risk to a similar degree.<br/>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <br/>Endoscopic Studies<br/>
                              </content>
                           </content>
                           <br/>The correlation between findings of short-term endoscopic studies with celecoxib and the relative incidence of clinically significant serious upper GI events with long-term use has not been established. Serious clinically significant upper GI bleeding has been observed in patients receiving celecoxib in controlled and open-labeled trials [<content styleCode="italics">seeÂ <linkHtml href="#LINK_7a44f63e-a433-4488-8e48-4e737b9afdf8">Warnings and Precautions (5.4)</linkHtml> and <linkHtml href="#LINK_c3b28510-93cc-4660-a903-8a090301704c">Clinical Studies (14.6)</linkHtml>
                           </content>]<br/>
                           <br/>A randomized, double-blind study in 430 RA patients was conducted in which an endoscopic examination was performed at 6 months. The incidence of endoscopic ulcers in patients taking celecoxib 200 mg twice daily was 4% vs. 15% for patients taking diclofenac SR 75 mg twice daily. However, celecoxib was not statistically different than diclofenac for clinically relevant GI outcomes in the CLASS trial [<content styleCode="italics">see <linkHtml href="#LINK_c3b28510-93cc-4660-a903-8a090301704c">Clinical Studies (14.6)</linkHtml>
                           </content>].<br/>
                           <br/>The incidence of endoscopic ulcers was studied in two 12-week, placebo-controlled studies in 2157 OA and RA patients in whom baseline endoscopies revealed no ulcers. There was no dose relationship for the incidence of gastroduodenal ulcers and the dose of celecoxib (50 mg to 400 mg twice daily). The incidence for naproxen 500 mg twice daily was 16.2 and 17.6% in the two studies, for placebo was 2 and 2.3%, and for all doses of celecoxib the incidence ranged between 2.7% to 5.9%. There have been no large, clinical outcome studies to compare clinically relevant GI outcomes with celecoxib and naproxen.<br/>
                           <br/>In the endoscopic studies, approximately 11% of patients were taking aspirin (â¤ 325 mg/day). In the celecoxib groups, the endoscopic ulcer rate appeared to be higher in aspirin users than in non-users. However, the increased rate of ulcers in these aspirin users was less than the endoscopic ulcer rates observed in the active comparator groups, with or without aspirin.</paragraph>
                     </text>
                     <effectiveTime value="20160517"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_58a8cb35-4b0b-4859-82c2-f2c6473949ca">
               <id root="3baeff8a-1ca8-4610-8aed-4c0609596cd2"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16. HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Celecoxib Capsules, 200 mg </content>are white cap/white body, size â2â hard gelatin capsule filled with white to off-white granular powder, imprinted with âYâ on the cap and â200â on the body with gold ink.<br/>
                     <br/>Â Â Â Â Â Â Â Â NDC 70882-129-14, Package of 14 Capsules (1 x 14 unit-of-dose blisters)<br/>
                     <br/>
                     <content styleCode="bold">
                        <content styleCode="italics">
                           <br/>Storage <br/>
                        </content>
                     </content>
                     <br/>Store at 20Â° to 25Â°C (68Â° to 77Â°F) [see USP Controlled Room Temperature]. </paragraph>
               </text>
               <effectiveTime value="20170620"/>
            </section>
         </component>
         <component>
            <section ID="LINK_785713a6-fc3e-47aa-bdb9-e3413aa71f26">
               <id root="785713a6-fc3e-47aa-bdb9-e3413aa71f26"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17. PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Medication Guide) that accompanies each prescription dispensed. Inform patients, families, or their caregivers of the following information before initiating therapy with celecoxib and periodically during the course of ongoing therapy.<br/>
                     <content styleCode="bold">
                        <content styleCode="italics">
                           <br/>Cardiovascular</content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics"> Thrombotic</content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics"> Events<br/>
                        </content>
                     </content>
                     <br/>Advise patients  to be alert for the  symptoms of cardiovascular thrombotic events,  including chest pain, shortness of breath,  weakness, or slurring of speech, and to report any of these  symptoms to their health care provider immediately [<content styleCode="italics">see <linkHtml href="#LINK_d3863c12-5bb3-4999-8cbe-53ff3302917d">Warnings and Precautions (5.1)</linkHtml>
                     </content>].<br/>
                     <content styleCode="bold">
                        <content styleCode="italics">
                           <br/>Gastrointestinal</content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics"> Bleeding,</content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics"> Ulceration,</content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics"> and</content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics"> Perforation<br/>
                        </content>
                     </content>
                     <br/>Advise patients  to report symptoms of ulcerations and bleeding, including epigastric pain, dyspepsia, melena, and hematemesis to their health care provider. In the setting of concomitant use of low-dose aspirin for cardiac  prophylaxis, inform patients of the increased risk for and the signs and  symptoms of GI bleeding [<content styleCode="italics">see <linkHtml href="#LINK_5069f2c7-1a91-4542-a9be-3aa4f8dbb0bc">Warnings and Precautions (5.2)</linkHtml>
                     </content>].<br/>
                     <content styleCode="bold">
                        <content styleCode="italics">
                           <br/>Hepatotoxicity<br/>
                        </content>
                     </content>
                     <br/>Inform patients of the  warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, pruritus, diarrhea, jaundice, right upper quadrant tenderness, and âflu-likeâ  symptoms). If these occur, instruct patients to stop celecoxib and seek immediate medical  therapy [<content styleCode="italics">see <linkHtml href="#LINK_123c45b9-a78a-40ef-ae49-d72c8d0bd6ba">Warnings and Precautions (5.3)</linkHtml>, <linkHtml href="#LINK_b8f55895-9834-4cd9-9451-c6e622fef01a">Use in Specific  Populations (8.6)</linkHtml>
                     </content>].<br/>
                     <content styleCode="bold">
                        <content styleCode="italics">
                           <br/>Heart Failure and  Edema<br/>
                        </content>
                     </content>
                     <br/>Advise patients  to be alert for the  symptoms of congestive heart failure including shortness of breath, unexplained weight gain,  or edema  and to contact their healthcare provider if such  symptoms occur [<content styleCode="italics">see <linkHtml href="#LINK_87f8faba-2740-4011-a06c-b2662ad92372">Warnings and Precautions (5.5)</linkHtml>
                     </content>].<br/>
                     <content styleCode="bold">
                        <content styleCode="italics">
                           <br/>Anaphylactic</content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics"> Reactions<br/>
                        </content>
                     </content>
                     <br/>Inform patients of the signs of an  anaphylactic reaction (e.g., difficulty breathing, swelling of the face or throat). Instruct patients to seek immediate emergency help if these occur [<content styleCode="italics">seeÂ </content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_4e64c33b-fc94-493c-9ebc-d5f9c2eeeaa0">Contraindications (4)</linkHtml>
                     </content>
                     <content styleCode="italics"> and </content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_06dd8f73-061b-470b-a423-4a7f979e165b">Warnings and Precautions (5.7 )</linkHtml>
                     </content>].<br/>
                     <content styleCode="bold">
                        <content styleCode="italics">
                           <br/>Serious Skin Reactions<br/>
                        </content>
                     </content>
                     <br/>Advise patients to stop celecoxib immediately if they develop any type of rash and to contact their healthcare provider as soon as possible [<content styleCode="italics">see <content styleCode="italics">
                           <linkHtml href="#LINK_5c76fc34-dcf3-40cc-b188-315fbbb7ff33">Warnings and Precautions (5.9)</linkHtml>
                        </content>
                     </content>].<br/>
                     <content styleCode="bold">
                        <content styleCode="italics">
                           <br/>Female F</content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics">ertility<br/>
                        </content>
                     </content>
                     <br/>Advise females of reproductive potential who desire pregnancy that NSAIDs, including celecoxib, may be associated with a reversible delay in ovulation [<content styleCode="italics">see <content styleCode="italics">
                           <linkHtml href="#LINK_eccf9714-b473-4b91-8ea0-cbe424df157a">Use in Specific Populations (8.3)</linkHtml>
                        </content>
                     </content>].<br/>
                     <content styleCode="bold">
                        <content styleCode="italics">
                           <br/>Fetal T</content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics">oxicity<br/>
                        </content>
                     </content>
                     <br/>Inform pregnant women to avoid use of celecoxib and other NSAIDs starting at 30 weeks of gestation because of the risk of the premature closing of the fetal ductus arteriosus [<content styleCode="italics">see</content>
                     <content styleCode="italics">Â <content styleCode="italics">
                           <linkHtml href="#LINK_4785b1f6-62b6-4f3b-86f3-1c6d5e6adb2d">Warnings and Precautions (5.10)</linkHtml>
                        </content> and <content styleCode="italics">
                           <linkHtml href="#LINK_f3aec266-21a6-4ac8-936c-cb2499eb89de">Use in Specific Populations (8.1)</linkHtml>
                        </content>
                     </content>].<br/>
                     <content styleCode="bold">
                        <content styleCode="italics">
                           <br/>Avoid C</content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics">oncomitant U</content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics">se of NSAIDs<br/>
                        </content>
                     </content>
                     <br/>Inform patients that the concomitant use of celecoxib with other NSAIDs or salicylates (e.g., diflunisal, salsalate) is not recommended due to the increased risk of gastrointestinal toxicity, and little or no increase in efficacy [seeÂ <content styleCode="italics">
                        <linkHtml href="#LINK_5069f2c7-1a91-4542-a9be-3aa4f8dbb0bc">Warnings and Precautions (5.2)</linkHtml>
                     </content>Â  andÂ <content styleCode="italics">
                        <linkHtml href="#LINK_93869e4e-072e-4529-aef5-761fb3a6d1b1">Drug Interactions (7)</linkHtml>
                     </content>]. Alert patients that NSAIDs may be present in âover the counterâ medications for treatment of colds, fever, or insomnia.<br/>
                     <content styleCode="bold">
                        <content styleCode="italics">
                           <br/>Use </content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics">of </content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics">NSAIDS </content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics">and </content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics">Low-Dose </content>
                     </content>
                     <content styleCode="bold">
                        <content styleCode="italics">Aspirin<br/>
                        </content>
                     </content>
                     <br/>Inform patients not to use low-dose aspirin concomitantly with celecoxib until they talk to their healthcare provider [see <content styleCode="italics">
                        <linkHtml href="#LINK_93869e4e-072e-4529-aef5-761fb3a6d1b1">Drug Interactions (7)</linkHtml>
                     </content>].<br/>
                     <content styleCode="bold">
                        <br/>Dispense with Medication Guide available at: <content styleCode="underline">www.aurobindousa.com/product-medication-guides</content>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20160517"/>
            </section>
         </component>
         <component>
            <section ID="LINK_b7711fec-0092-4371-a80f-d52cf20fd318">
               <id root="0ae9a7ea-0f9f-4abd-bb56-ea3dce3d9065"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <title>Medication Guide for Nonsteroidal Anti-inflammatory Drugs (NSAIDs)</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">What is the most important information I should know about medicines called Nonsteroidal Anti-inflammatory Drugs (NSAIDs)?<br/>
                     </content>
                     <content styleCode="bold">
                        <br/>NSAIDs can cause serious side effects, including:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>
                        <content styleCode="bold"> Increased risk of a  heart attack or stroke that can  lead to death.</content> This risk may  happen early in treatment and  may increase:    <list listType="unordered" styleCode="Circle">
                           <item> with increasing doses of NSAIDs</item>
                           <item> with longer use of NSAIDs</item>
                        </list>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold"> Do not take NSAIDs right before or after a  heart surgery called a  âcoronary artery bypass graft (CABG).â<br/>
                     </content>
                     <content styleCode="bold">
                        <br/>Avoid taking NSAIDs after a  recent heart attack, unless your healthcare provider tells you to. You may  have an  increased risk of  another heart attack if you take NSAIDs after a  recent heart attack.</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>
                        <content styleCode="bold"> Increased risk of  bleeding, ulcers, and tears (perforation) of the esophagus (tube leading from the mouth to the stomach), stomach and  intestines:</content>
                        <list listType="unordered" styleCode="Circle">
                           <item> anytime during use</item>
                           <item> without warning symptoms</item>
                           <item> that may cause death</item>
                        </list>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold"> The risk of getting an  ulcer or bleeding increases with:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>past history of stomach ulcers, or stomach or intestinal bleeding  with use of NSAIDs</item>
                     <item>taking  medicines called  âcorticosteroidsâ, âanticoagulantsâ, âSSRIsâ or âSNRIsâ</item>
                     <item>increasing doses of NSAIDs</item>
                     <item>older age</item>
                     <item>longer use of NSAIDs</item>
                     <item>poor health</item>
                     <item> smoking</item>
                     <item>advanced liver disease</item>
                     <item>drinking alcohol</item>
                     <item>bleeding problems</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold"> NSAIDs should only  be used:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>exactly as prescribed</item>
                     <item>at the  lowest dose possible for  your treatment</item>
                     <item>for the shortest  time needed</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">What are NSAIDs?<br/>
                     </content>
                     <br/>NSAIDs are used to treat pain and redness,  swelling, and heat  (inflammation) from  medical conditions such as  different types of arthritis,  menstrual cramps, and other types of short-term pain.<br/>
                     <content styleCode="bold">
                        <br/>Who</content>
                     <content styleCode="bold"> should</content>
                     <content styleCode="bold"> not</content>
                     <content styleCode="bold"> take</content>
                     <content styleCode="bold"> NSAIDs?</content>
                     <content styleCode="bold">
                        <br/>
                     </content>
                     <content styleCode="bold">
                        <br/>Do not take NSAIDs:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>if you have had an  asthma attack, hives, or other allergic reaction  with aspirin  or any other  NSAIDs.</item>
                     <item>right  before or after heart bypass surgery.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold"> Before taking NSAIDS, tell your healthcare provider about all of  your medical conditions, including if  you:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>have liver or kidney problems</item>
                     <item>have high blood pressure</item>
                     <item>have asthma</item>
                     <item>are pregnant or plan to become pregnant. Talk to your healthcare provider if  you are considering taking NSAIDs during pregnancy. <content styleCode="bold"> You should not take NSAIDs after 29 weeks  of pregnancy</content>
                     </item>
                     <item>are breastfeeding or plan to breast feed<content styleCode="bold">.</content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold"> Tell your healthcare provider about all of  the medicines you take, including prescription or over-the-counter medicines, vitamins or herbal s</content>
                     <content styleCode="bold">upplements. </content>NSAIDs and  some other  medicines can  interact with each other and cause serious side effects. <content styleCode="bold"> Do not start taking any  new medicine without  talking to  your healthcare provider first.<br/>
                     </content>
                     <content styleCode="bold">
                        <br/>What</content>
                     <content styleCode="bold"> are</content>
                     <content styleCode="bold"> the</content>
                     <content styleCode="bold"> possible</content>
                     <content styleCode="bold"> side</content>
                     <content styleCode="bold"> effects o</content>
                     <content styleCode="bold">f  NSAIDs?<br/>
                     </content>
                     <content styleCode="bold">
                        <br/>NSAIDs can  cause serious side effects, including:<br/>
                     </content>
                     <content styleCode="bold">
                        <br/>See âWhat is the most important information I  should know about Â  medicines Â  called Nonsteroidal Â  Anti-inflammatory Â  Drugs Â  (NSAIDs)?</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>new or worse high blood pressure</item>
                     <item>heart failure</item>
                     <item>liver problems including liver failure</item>
                     <item>kidney problems including kidney failure</item>
                     <item>low red blood cells (anemia)</item>
                     <item>life-threatening skin reactions</item>
                     <item>life-threatening allergic reactions</item>
                     <item>
                        <content styleCode="bold"> Other Â  side Â  effects Â  of Â  NSAIDs Â  include: Â </content>stomach pain, constipation, diarrhea, gas, heartburn, nausea, vomiting, and dizziness.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold"> Get emergency help right away  if you get any  of the following symptoms:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>shortness of breath or trouble breathing</item>
                     <item>slurred speech</item>
                     <item>chest pain</item>
                     <item> swelling of the face or throat</item>
                     <item> weakness in one part or side of your body</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold"> Stop taking your NSAID and call your healthcare provider right away if you get any of  the following symptoms:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>Nausea</item>
                     <item> vomit blood</item>
                     <item> more tired  or weaker than  usual</item>
                     <item>there is blood in your  bowel movement or it is black and sticky like tar</item>
                     <item> diarrhea</item>
                     <item>itching</item>
                     <item>unusual weight gain</item>
                     <item>your skin or eyes look  yellowÂ Â Â Â Â  </item>
                     <item>skin rash or  blisters with fever</item>
                     <item>indigestion or  stomach pain</item>
                     <item> swelling Â of the  arms, legs, hands and feet</item>
                     <item> flu-like symptoms</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold"> If you take too much of your NSAID, call your healthcare provider or get  medical help right away.<br/>
                     </content>
                     <br/>These are not all the possible  side effects of NSAIDs. For  more information, ask  your healthcare provider or pharmacist about NSAIDs. Call your doctor for  medical advice about side effects.  You may report side effects to FDA at  1-800-FDA-1088.<br/>
                     <content styleCode="bold">
                        <br/>Other</content>
                     <content styleCode="bold"> information</content>
                     <content styleCode="bold"> about N</content>
                     <content styleCode="bold">SAIDs</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>Aspirin is an  NSAID but it does not increase the chance of a heart attack. Aspirin  can cause bleeding in the brain,  stomach, and intestines. Aspirin can also cause ulcers in the  stomach and intestines.</item>
                     <item> Some NSAIDs are sold in  lower doses  without a prescription (over-the counter). Talk to  your healthcare provider before using  overÂ­ the-counter NSAIDs for  more than 10  days.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold"> General</content>
                     <content styleCode="bold"> information</content>
                     <content styleCode="bold"> about</content>
                     <content styleCode="bold"> the s</content>
                     <content styleCode="bold">afe  and effective use of NSAIDs<br/>
                     </content>
                     <br/>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use NSAIDs for a condition for  which it  was not prescribed. Do not give NSAIDs to other people, even if they have the same  symptoms that you have. It may harm them.<br/>
                     <br/>If  you would like more information about NSAIDs, talk  with your healthcare provider.  You can ask your pharmacist or healthcare provider for information about NSAIDs that is written for health professionals.<br/>
                     <br/>For more information, contact Cambridge Therapeutic Technologies at 1-844-810-0004.<br/>
                     <br/>This Medication Guide has been approved by the U.S. Food and Drug  Administration.<br/>
                     <content styleCode="bold">
                        <br/>Dispense with Medication Guide <content styleCode="underline">
                           <br/>
                        </content>
                     </content>
                     <br/>Manufactured by:<br/>
                     <content styleCode="bold">Aurobindo Pharma Limited</content>
                     <br/>Unit-VII (SEZ)<br/>Mahaboob Nagar (Dt)-509302<br/>India<br/>
                     <br/>Distributed by Cambridge Therapeutic Technologies, LLC<br/>Teaneck, NJ 07666</paragraph>
                  <paragraph>Packaged by Legacy Pharmaceutical Packaging, LLC<br/>Earth City, MO 63045</paragraph>
                  <paragraph>Revised: 05/2017<br/>20707</paragraph>
               </text>
               <effectiveTime value="20170620"/>
            </section>
         </component>
         <component>
            <section ID="LINK_c02120b3-60a0-4622-91b9-96acbe3a1bf9">
               <id root="faca6305-9956-4c9d-90b6-1941f1bdc7e8"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - 200 mg</title>
               <text>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20170620"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>Celecoxib Capsules 200 mg</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="celecoxib-capsules---aurobindo-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>